Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaeal1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

<12/04/2007> Erich Leese

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:54:37 ON 03 JUN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:54:48 ON 03 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JUN 2008 HIGHEST RN 1024742-83-3
DICTIONARY FILE UPDATES: 2 JUN 2008 HIGHEST RN 1024742-83-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10539708new.str



chain nodes :
29 30 31 32 33 35 36 37 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28
chain bonds :
2-31 7-30 10-26 18-32 22-33 23-29 29-30 29-35 29-36 30-37 30-38
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-19 6-21 7-8 7-12 8-9 9-10 10-11 11-12 13-14
13-18 14-15 14-26 15-16 15-28 16-17 17-18 19-20 19-22 20-21 20-25 22-23
23-24 24-25 26-27 27-28
exact/norm bonds :
1-2 1-6 2-3 2-31 3-4 4-5 5-6 7-8 7-12 7-30 8-9 9-10 10-11 10-26 11-12
19-20 19-22 20-25 22-23 22-33 23-24 23-29 24-25 26-27
exact bonds :
5-19 6-21 14-26 15-28 18-32 20-21 27-28 29-30 29-35 29-36 30-37 30-38
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS

L1 STRUCTURE UPLOADED

<12/04/2007> Erich Leese

```
=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 16:55:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       44 TO ITERATE

100.0% PROCESSED       44 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

L2            2 SEA SSS FUL L1

=> file capluis
'CAPLUIS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 178.36     178.57

FILE 'CAPLUS' ENTERED AT 16:55:18 ON 03 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Jun 2008  VOL 148 ISS 23
FILE LAST UPDATED: 2 Jun 2008  (20080602/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2 full
L3            1 L2
```

=> d ibib abs hitstr

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:525895 CAPLUS
DOCUMENT NUMBER: 141:89095
TITLE: Preparation of 3-substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-ones as central nervous system agents
PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10259382	A1	20040701	DE 2002-10259382	20021218
WO 2004055024	A1	20040701	WO 2003-EP14423	20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300529	A1	20040709	AU 2003-300529	20031217
EP 1572698	A1	20050914	EP 2003-813137	20031217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060142317	A1	20060629	US 2005-539708	20051230

PRIORITY APPLN. INFO.: DE 2002-10259382 A 20021218
WO 2003-EP14423 W 20031217

OTHER SOURCE(S): MARPAT 141:89095
GI



I



II

AB Title compds. [I; A = O, S, SO, NR5, CH2; R5 = N, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl; R4 = H, Me; m, n = 0, 1; R1 = alkylene; R2 = 1,4-piperazinylene, 1,4-piperidinylene, 1,3-pyrrolidinylene, 1,4-homopiperazinylene, etc.; R3 = (substituted) (aryl- or heteroaryl-condensed) 5-membered heteroaryl], were prepared Thus, title compound (II) bound to 5-HT1A and 5-HT1B receptors with Ki = 0.5 nM and 0.6 nM, resp.

IT 713508-93-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 713508-93-1 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

=>
Uploading C:\Program Files\Stnexp\Queries\10539708.str





chain nodes :
13 20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
4-13 5-22 6-20
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 8-10 9-12 10-11 11-12
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 4-13 5-6 5-22 6-20 7-8 8-9 8-10 9-12
10-11 11-12
isolated ring systems :
containing 1 :

G1:O,S,N,CH2

G2:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 20:CLASS 22:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS
L4 STR



G1 O,S,N,CH2

G2 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l4 full
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 16:56:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 31984 TO ITERATE

100.0% PROCESSED 31984 ITERATIONS 4283 ANSWERS
SEARCH TIME: 00.00.02

L5 4283 SEA SSS FUL L4

L6 44 L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	363.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'CAPLUS' ENTERED AT 16:56:09 ON 03 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

<12/04/2007> Erich Leese

FILE COVERS 1907 - 3 Jun 2008 VOL 148 ISS 23
FILE LAST UPDATED: 2 Jun 2008 (20080602/ED)

=> s l6 full
L7   44 L5

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1066126 CAPLUS
DOCUMENT NUMBER: 147:522185
TITLE: Synthesis of isomeric enamine derivatives of fused cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones. Stereoelectronic effect on the regioselectivity
AUTHOR(S): Lilienkampf, Annamaria; Heikkinen, Sami; Mutikainen, Ilpo; Wahala, Kristiina
CORPORATE SOURCE: Laboratory of Organic Chemistry, Department of Chemistry, University of Helsinki, Helsinki, 00014, Finland
SOURCE: Synthesis (2007), (17), 2699-2705
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:522185
AB A regioselective synthesis of enamine and enaminone derivs. of fused cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones is reported. The enamine vs. enaminone product in the condensation reaction with N,N-dimethylformamide dimethylacetal (DMFDMA) was shown to depend on the conformation of the cycloalkeno ring fused to the pyrimidinone moiety. The ring conformation and the stereoelectronic effect of the amidine α-protons were studied by X-ray crystallog. In deuterium exchange expts., the amidine-ketene-N,N-acetal tautomerism was shown to be prohibited with larger ring systems consequently yielding the enaminone products.
IT 101662-28-6P 813458-88-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(regioselective synthesis of isomeric enamine derivs. of fused cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones)
RN 101662-28-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl- (CA INDEX NAME)



RN 813458-88-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:484949 CAPLUS
DOCUMENT NUMBER: 146:475681
TITLE: Immunomodulatory heterocyclic compounds that target and inhibit the pY binding site of tyrosine kinase p56lck SH2 domain
INVENTOR(S): Mackerell, Alexander; Hayashi, Jun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 90pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070099970	A1	20070503	US 2006-507038	20060821
WO 2008024759	A2	20080228	WO 2007-US76402	20070821

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-709972P P 20050819
US 2006-507038 A 20060821
OTHER SOURCE(S): MARPAT 146:475681

AB Small mol.-weight non-peptidic compds. block lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.

IT 442674-70-6 442674-72-8 442675-13-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunomodulatory heterocyclic compound inhibitors of pY binding site of tyrosine kinase p56lck SH2 domain)

RN 442674-70-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-[3-[(2,4-dimethoxyphenyl)amino]-3-oxopropyl]-5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 442674-72-8 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-[3-[(3,4-dimethoxyphenyl)amino]-3-oxopropyl]-5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 442675-13-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-N-[3-[(2-methoxy-5-methylphenyl)amino]-3-oxopropyl]-4-oxo- (CA INDEX NAME)



L7 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:433840 CAPLUS
DOCUMENT NUMBER: 146:441502
TITLE: Composition and synthesis of new benzamides and related compounds for inhibition of HIV replication
INVENTOR(S): Rana, Tariq M.
PATENT ASSIGNEE(S): University of Massachusetts, USA
SOURCE: PCT Int. Appl., 160pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007044565	A2	20070419	WO 2006-US39228	20061006
WO 2007044565	A3	20070607		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070099919	A1	20070503	US 2006-544068	20061006

PRIORITY APPLN. INFO.: US 2005-725043P P 20051006
OTHER SOURCE(S): MARPAT 146:441502
GI



I



II

AB The invention provides compds. of formula I and compns. for inhibiting Vif and methods for treating viral infection, e.g., HIV infection. Compds. of formula I wherein R is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (hetero)aryl, and (un)substituted (hetero)cycloalkyl; R1, R2 and R3 are independently H, NO2, NH2, CF3, Br, Cl, F and I; Y is CO, NHCO and derivs., SO2NH and derivs., NHCONH, NHCO2, OCONH and CONH2 and derivs.; Z us absent, O, S, NH and derivs., CH2, SO2, C1-6 alkyl-OH and derivs., CO, C1-6 alkyl-NH and derivs.; and their enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 2-iodobenzoyl chloride with 2-methoxyaniline; the resulting N-(2-methoxyphenyl)-2-iodobenzamide underwent sulfanylation with 4-nitrothiophenol to give compound II. All the invention compds. were evaluated for their Vif inhibitory activity. These compound may be useful in the treatment of viral infection such as HIV infections.

IT 455920-07-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of arylsulfanylbenzamides and related compds. as Vif inhibitors useful in the treatment of HIV infections)

RN 455920-07-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-(2-ethoxyphenyl)-5,6,7,8-tetrahydro-7-methyl-4-oxo- (CA INDEX NAME)



L7 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:922111 CAPLUS
DOCUMENT NUMBER: 145:306767
TITLE: Thienyl compounds for treating virus-related conditions
INVENTOR(S): Olivo, Paul D.; Buscher, Benjamin A.; Dyall, Julie; Jockel-Balsarotti, Jennifer I.; O'Guin, Andrew K.; Roth, Robert M.; Franklin, Gary W.; Starkey, Gale W.
PATENT ASSIGNEE(S): Apath, LLC, USA
SOURCE: PCT Int. Appl., 343pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006093518	A2	20060908	WO 2005-US22559	20050625
WO 2006093518	A3	20070322		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-582996P P 20040625
OTHER SOURCE(S): MARPAT 145:306767

AB The invention discloses thienyl compds. (particularly (thien-2-yl)amino compds.), pharmaceutical compns. and kits comprising such compds., and uses of such compds. for preparing medicaments and treating virus-related conditions in animals.

IT 369394-92-3 370853-41-1 384351-55-7
433254-84-3 433975-50-9 449190-71-0
449190-92-5 459416-27-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thienyl compds. for treating virus-related conditions)

RN 369394-92-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-7-methyl-4-oxo-, (1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide (9CI) (CA INDEX NAME)



RN 370853-41-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)hydrazide (9CI) (CA INDEX NAME)



RN 384351-55-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-(2-furanylmethyl)-5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 433254-84-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-α-methyl-4-oxo-, methyl ester (CA INDEX NAME)



RN 433975-50-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, N-(2-furanylmethyl)-5,6,7,8-tetrahydro-7-methyl-4-oxo- (CA INDEX NAME)



RN 449190-71-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, α-ethyl-5,6,7,8-tetrahydro-4-oxo-, 2-methylpropyl ester (CA INDEX NAME)



RN 449190-92-5 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-6-methyl-2-[[2-(5,6,7,8-tetrahydro-7-methyl-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]amino]-, ethyl ester (CA INDEX NAME)



RN 459416-27-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-α,7-dimethyl-4-oxo-, cyclohexyl ester (CA INDEX NAME)


Me
S
N
Me
O
N
CH
C
O
O

L7 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1178247 CAPLUS
DOCUMENT NUMBER: 144:69793
TITLE: Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs
AUTHOR(S): Kling, Andreas; Lange, Udo E. W.; Mack, Helmut; Bakker, Margot H. M.; Drescher, Karla U.; Hornberger, Wilfried; Hutchins, Charles W.; Moeller, Achim; Mueller, Reinhold; Schmidt, Martin; Unger, Liliane; Wicke, Karsten; Schellhaas, Kurt; Steiner, Gerd
CORPORATE SOURCE: Neuroscience Discovery, Abbott GmbH & Co. KG, Ludwigshafen, D-67008, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(24), 5567-5573
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:69793
GI



I

AB 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a mode of action the objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 2-methoxyphenyl- or isoquinoline substituted piperazine derivs. as leads and the corresponding results are discussed. Isoquinoline analog I displayed high affinity and an antagonistic mode of action for the 5-HT1A and the 5-HT1B receptors and was characterized further with respect to selectivity, elec. stimulated [3H]5-HT release and in vivo efficacy.

IT 281657-31-6P 281657-43-0P 281657-46-3P
281657-47-4P 385821-43-2P 708972-34-3P
743409-73-6P 750559-17-2P 754965-99-6P
759446-14-5P 766496-55-3P 773043-17-7P
786629-89-8P 792895-04-6P 872005-20-4P
872005-21-5P 872005-22-6P 872005-23-7P
872005-24-8P 872005-25-9P 872005-26-0P

<12/04/2007> Erich Leese

872005-27-1P 872005-28-2P 872005-29-3P
872005-35-1P 872005-36-2P 872005-37-3P
872005-38-4P 872005-39-5P 872005-40-8P
872005-41-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, 5-HT1A and 5-HT1B antagonistic activity, antidepressant activity, and SAR of (arylpiperazinylethyl)tetrahydropyridothienopyrimidinones using heterocyclization and amination with arylpiperazines as the key steps)

RN 281657-31-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-methoxy[1,1'-biphenyl]-3-yl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 281657-43-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-46-3 CAPLUS
CN Benzonitrile, 2-[4-[2-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 281657-47-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 385821-43-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 708972-34-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-isoquinolinyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 743409-73-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 750559-17-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 754965-99-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,5-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 759446-14-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 766496-55-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 773043-17-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,5-dichloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 786629-89-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 792895-04-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-quinazolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 872005-20-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(4-[1,1'-biphenyl]-2-yl-1-piperazinyl)ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-21-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 872005-22-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-[2-(2,2-dimethylpropoxy)phenyl]-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-23-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-phenoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 872005-24-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[2-(phenylmethoxy)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 872005-25-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-5-methylphenyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 872005-26-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-[2-methoxy-5-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 872005-27-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-28-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-29-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4,5-dichloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-35-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,3-dihydro-7-benzofuranyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-36-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(4-benzo[b]thien-7-yl-1-piperazinyl)ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 872005-37-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 872005-38-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 872005-39-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 872005-40-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-isoquinolinyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 872005-41-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(8-isoquinolinyl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



IT 281657-01-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, 5-HT1A and 5-HT1B antagonistic activity, antidepressant activity, and SAR of (arylpiperazinylethyl)tetrahydropyridothienopyrimidinones using heterocyclization and amination with arylpiperazines as the key steps)
RN 281657-01-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:395446 CAPLUS
DOCUMENT NUMBER: 142:406543
TITLE: TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators
INVENTOR(S): Xu, Wei; Zheng, Wentao; Baly, Deborah Lynn; Galan, Adam Antoni; Ibrahim, Mohamed Abdulkader; Jaeger, Christopher; Kearney, Patrick; Leahy, James William; Lewis, Gary Lee; McMillan, Kirk; Noguchi, Robin Tammie; Nuss, John M.; Parks, Jason Jevious; Schnepp, Kevin Luke; Shi, Xian; Williams, Matthew Alan
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040355	A2	20050506	WO 2004-US35469	20041022
WO 2005040355	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283313	A1	20050506	AU 2004-283313	20041022
CA 2542064	A1	20050506	CA 2004-2542064	20041022
EP 1678121	A2	20060712	EP 2004-796442	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007527412	T	20070927	JP 2006-536928	20041022
US 20070208166	A1	20070906	US 2006-576932	20061019

PRIORITY APPLN. INFO.: US 2003-514377P P 20031024
WO 2004-US35469 W 20041022

OTHER SOURCE(S): MARPAT 142:406543

AB The invention provides compds. and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Thus, N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,d][1,4]diazepine-3-carboxamide was synthesized. This compound exhibited an IC50 with JIK kinase of <50 nM and an IC50 with TAO kinase of between 50 and 500 nM.

IT 442675-24-3
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators)
RN 442675-24-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-N-[4-[(6-methoxy-2-benzothiazolyl)amino]-4-oxobutyl]-4-oxo- (CA INDEX NAME)



L7 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1124651 CAPLUS
DOCUMENT NUMBER: 142:74590
TITLE: Preparation of fused thienopyrimidinones as 17β-hydroxysteroid dehydrogenase (17β-HSD) inhibitors
INVENTOR(S): Waehaelae, Kristiina; Lilienkampf, Annamaria; Alho, Sari; Huhtinen, Kaisa; Johansson, Nina; Koskimies, Pasi; Vihko, Kimmo
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B. V., Neth.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004110459	A1	20041223	WO 2004-EP6231		20040609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20050032778	A1	20050210	US 2004-861922		20040607
AU 2004246791	A1	20041223	AU 2004-246791		20040609
CA 2527591	A1	20041223	CA 2004-2527591		20040609
EP 1635840	A1	20060322	EP 2004-739738		20040609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1784234	A	20060607	CN 2004-80012636		20040609
BR 2004011319	A	20060718	BR 2004-11319		20040609
JP 2006527227	T	20061130	JP 2006-515870		20040609
MX 2005PA12871	A	20060731	MX 2005-PA12871		20051129
US 20080103131	A1	20080501	US 2007-967989		20071231
PRIORITY APPLN. INFO.:			US 2003-477017P	P	20030610
			US 2004-861922	A3	20040607
			WO 2004-EP6231	W	20040609

OTHER SOURCE(S): MARPAT 142:74590
GI



I



II

AB Use of title compds. [I; R1, R2 = H, alkyl; R1R2 = atoms to form a 5-8 membered (substituted) (heterocyclic) (unsatd.) ring; R3R4 = atoms to form a 5-8 membered (substituted) (unsatd.) ring; with provisos] for manufacture of a medicament for the treatment/prevention of a steroid hormone dependent disease requiring the inhibition of 17β-hydroxysteroid dehydrogenase is claimed. Thus, Et 2-amino-4,5,6,7-tetrahydrobenzothiophene-3-carboxylate, ε-caprolactam, and POCl3 were refluxed in CH2Cl2 to give 90% title compound (II). II at 10 μM gave 45.9% inhibition of 17β-HSD type 1.

IT 813458-88-7P 813458-89-8P 813458-93-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of fused thienopyrimidinones as 17β-hydroxysteroid dehydrogenase inhibitors)

RN 813458-88-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-2,3-dimethyl- (CA INDEX NAME)



RN 813458-89-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 3-ethyl-6,7-dihydro- (CA INDEX NAME)



RN 813458-93-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-7-carboxaldehyde, 8-chloro-3,4,5,6,7,8-

hexahydro-3-methyl-4-oxo- (CA INDEX NAME)



IT 40277-29-0P 101662-28-6P 813459-10-8P
813459-14-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused thienopyrimidinones as 17β-hydroxysteroid dehydrogenase inhibitors)

RN 40277-29-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-methyl- (CA INDEX NAME)



RN 101662-28-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl- (CA INDEX NAME)



RN 813459-10-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-methyl- (CA INDEX NAME)



RN 813459-14-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-7-carboxaldehyde, 8-chloro-3,4,5,6-tetrahydro-3-methyl-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1038771 CAPLUS
DOCUMENT NUMBER: 143:286364
TITLE: Synthesis of certain propanolamines as potential adrenoceptor antagonists
AUTHOR(S): Khalil, N. A.; Botros, S.; Soliman, L. N.; Amin, F. M.; El-Zanfaly, S.
CORPORATE SOURCE: Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
SOURCE: Bulletin of the Faculty of Pharmacy (Cairo University) (2002), 40(2), 23-29
CODEN: BFPHA8; ISSN: 1110-0931
PUBLISHER: Cairo University, Faculty of Pharmacy
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:286364
GI



I



II

AB Amino(hydroxy)-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones I (X = CH2, R1 = H; X = 1,4-C6H4OCH2, R1 = Me; R2 = H, R3 = n-Pr, Me2CH, Me3C, PhCH2, PhCH2CH2, cyclopentyl; R2 = R3 = Et, PhCH2; R2R3N = 1-pyrrolidinyl, 4-morpholinyl, 1-piperidinyl) were synthesized by ring opening of epoxides II with the corresponding primary and secondary amines. Pharmacol. screening showed that the compds. I (X = CH2, R1 = H; X = 1,4-C6H4OCH2, R1 = Me; R2R3N = 1-pyrrolyl, 1-piperidinyl) produced initial myocardial depressant effect, however only compds. I (X = 1,4-C6H4OCH2; R1 = Me; R2R3N = 1-pyrrolidinyl, 1-piperidinyl) antagonized the stimulant effect of isoprenaline on isolated frog heart.

IT 864234-08-2P 864234-10-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of amino(hydroxy)propyl-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones as myocardial depressants and adrenoceptor antagonists via epoxide ring opening with amines)

RN 864234-08-2 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 864234-10-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-(1-piperidinyl)propyl]- (CA INDEX NAME)



IT 864234-03-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino(hydroxy)propyl-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones as myocardial depressants and adrenoceptor antagonists via epoxide ring opening with amines)
RN 864234-03-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-oxiranylmethyl)- (CA INDEX NAME)



IT 864234-02-6P 864234-04-8P 864234-05-9P
864234-06-0P 864234-07-1P 864234-09-3P
864234-11-7P 864234-12-8P 864234-13-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of amino(hydroxy)propyl-functionalized hexahydrobenzo[b]thieno[2,3-d]pyrimidinones as myocardial depressants and adrenoceptor antagonists via epoxide ring opening with amines)
RN 864234-02-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4-one, 3,3'-(2-hydroxy-1,3-propanediyl)bis[5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 864234-04-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-(propylamino)propyl]- (CA INDEX NAME)



RN 864234-05-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-[(1-methylethyl)amino]propyl]- (CA INDEX NAME)



RN 864234-06-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(diethylamino)-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864234-07-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864234-09-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(cyclopentylamino)-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864234-11-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-[(phenylmethyl)amino]propyl]- (CA INDEX NAME)



RN 864234-12-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-hydroxy-3-[(2-phenylethyl)amino]propyl]- (CA INDEX NAME)



RN 864234-13-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-[bis(phenylmethyl)amino]-2-hydroxypropyl]-5,6,7,8-tetrahydro-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:525895 CAPLUS
DOCUMENT NUMBER: 141:89095
TITLE: Preparation of 3-substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-ones as central nervous system agents
PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10259382	A1	20040701	DE 2002-10259382	20021218
WO 2004055024	A1	20040701	WO 2003-EP14423	20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300529	A1	20040709	AU 2003-300529	20031217
EP 1572698	A1	20050914	EP 2003-813137	20031217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060142317	A1	20060629	US 2005-539708	20051230

PRIORITY APPLN. INFO.: DE 2002-10259382 A 20021218
WO 2003-EP14423 W 20031217

OTHER SOURCE(S): MARPAT 141:89095
GI



I



II

AB Title compds. [I; A = O, S, SO, NR5, CH2; R5 = N, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl; R4 = H, Me; m, n = 0, 1; R1 = alkylene; R2 = 1,4-piperazinylene, 1,4-piperidinylene, 1,3-pyrrolidinylene, 1,4-homopiperazinylene, etc.; R3 = (substituted) (aryl- or heteroaryl-condensed) 5-membered heteroaryl], were prepared Thus, title compound (II) bound to 5-HT1A and 5-HT1B receptors with Ki = 0.5 nM and 0.6 nM, resp.

IT 713508-85-1P 713508-86-2P 713508-87-3P
713508-88-4P 713508-89-5P 713508-90-8P
713508-91-9P 713508-92-0P 713508-93-1P
713508-94-2P 713508-95-3P 713508-96-4P
713508-97-5P 713508-98-6P 713508-99-7P
713509-00-3P 713509-01-4P 713509-02-5P
713509-03-6P 713509-04-7P 713509-06-9P
713509-08-1P 713509-09-2P 713509-10-5P
713509-11-6P 713509-12-7P 713509-13-8P
713509-14-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 713508-85-1 CAPLUS

CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 713508-84-0
CMF C23 H25 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 713508-86-2 CAPLUS
CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 713508-87-3 CAPLUS
CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[(1S)-1-methyl-2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 713508-88-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-

(CA INDEX NAME)



RN 713508-89-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4-chloro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713508-90-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[5-(trifluoromethyl)-2-benzothiazolyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 713508-91-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-2-benzothiazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713508-92-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzimidazol-2-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713508-93-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 713508-94-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-benzoxazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713508-95-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-benzothiazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713508-96-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 713508-97-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 713508-98-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(7-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713508-99-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-00-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-1-methyl-1H-indol-3-yl)-1-piperidinyl]ethyl]-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-01-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-3-benzofuranyl)-1-piperidinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-02-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-3-benzofuranyl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-03-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1H-indol-3-yl)-1-piperidinyl]ethyl]-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-04-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713509-06-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 713509-05-8
CMF C24 H26 N6 O S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 713509-08-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1-piperidinyl]ethyl]-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 713509-07-0
CMF C24 H28 N6 O S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 713509-09-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-10-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[5-(2-thienyl)-1H-pyrazol-3-yl]-1-piperidinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-11-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzotriazol-1-yl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 713509-12-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-13-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1-phenyl-1H-tetrazol-5-yl)-1-piperazinyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-14-9 CAPLUS
CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[(1R)-1-methyl-2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 713509-15-0 713509-16-1 713509-17-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of dihydrothienopyrimidinones as central nervous system agents)
RN 713509-15-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(4-benzo[b]thien-3-yl-3,6-dihydro-1(2H)-pyridinyl)ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 713509-16-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,1-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 713509-17-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(5-methoxy-1H-indol-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



IT 281657-00-9P 281657-01-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydrothienopyrimidinones as central nervous system agents)
RN 281657-00-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-hydroxyethyl)-7-methyl- (CA INDEX NAME)



RN 281657-01-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)


N
S
Me
N
N
ClCH2—CH2
O

L7 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:31458 CAPLUS
DOCUMENT NUMBER: 136:85831
TITLE: Preparation of 5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-ones for the treatment of cerebral ischemia
INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Szabo, Laszlo; Behl, Berthold; Garcia-Ladona, Francisco Javier; Unger, Liliane
PATENT ASSIGNEE(S): Knoll Ag, Germany
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002569	A1	20020110	WO 2001-EP7573	20010702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10031389	A1	20020117	DE 2000-10031389	20000703
PRIORITY APPLN. INFO.:			DE 2000-10031389 A	20000703

OTHER SOURCE(S): MARPAT 136:85831
GI



I

AB Title compds. [I; R1 = H, C1-4 alkyl] and salts thereof were prepared as 5-HT1A agonists. Thus, a mixture of 3-(2-chloroethyl)-7-acetyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 8-(1-piperazinyl)quinoline (preparation given) and K2CO3 in xylene was refluxed for 18 h to give 7-acetyl-3-[2-(4-(8-quinolinyl)-1-piperazinyl)ethyl]-5,6,7,8-[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one which was refluxed with 15% HCl for 3 h to give 71% 3-[2-(4-(8-quinolinyl)-1-piperazinyl)ethyl]-5,6,7,8-[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one. Tested I showed affinity for the 5-HT1A receptor with Ki = 0.15-0.95 nM in

HEK 293 cells.

IT 385821-43-2P 385821-46-5P 385821-47-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydropyridothienopyrimidinones for treatment of cerebral ischemia)

RN 385821-43-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 385821-46-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 385821-47-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 281657-01-0 385821-42-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetrahydropyridothienopyrimidinones for treatment of cerebral ischemia)
RN 281657-01-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 385821-42-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-3-(2-chloroethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)



IT 385821-41-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydropyridothienopyrimidinones for treatment of cerebral ischemia)
RN 385821-41-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:31457 CAPLUS
DOCUMENT NUMBER: 136:102403
TITLE: Preparation of fused thieno[2,3-d]pyrimidines for the treatment of cerebral ischemia
INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Szabo, Laszlo; Behl, Berthold; Garcia-Ladona, Francisco Javier; Unger, Liliane
PATENT ASSIGNEE(S): Knoll G.m.b.H., Germany
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002568	A1	20020110	WO 2001-EP7569	20010702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10031390	A1	20020117	DE 2000-10031390	20000703
PRIORITY APPLN. INFO.:			DE 2000-10031390 A	20000703

OTHER SOURCE(S): CASREACT 136:102403; MARPAT 136:102403
GI



I

AB Title compds. [I; A = O; B = H, Me; DE = (substituted) (CH2)3, (CH2)4; X = N; Y = CH2, CH2CH2, (CH2)3, CH2CH; Z = N, C, CH; n = 2-4; R2 = (substituted) (anellated) Ph, pyridyl, pyrimidinyl, pyrazinyl] and salts thereof were prepared as 5-HT1A agonists. Thus, a mixture of 2-ethoxymethylidenylamino-3-carbonylethoxy-4,7-dihydro-5H-thieno[2,3-d]pyran (preparation given) and 2-[4-(1-isoquinolinyl)-1-piperazinyl]ethylamine (preparation given) in EtOH was refluxed followed for stirring for 3 days at room temperature to give 89% 3-[2-(4-(1-isoquinolinyl)-1-piperazinyl)ethyl]-3,5,6,8-tetrahydro-4H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one. Tested I showed affinity for 5-HT1A receptors with K1 = 0.16-3.30 nM in HEK 293 cells.
IT 388088-84-4P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)
(preparation of fused thienopyrimidines for treatment of cerebral ischemia)
RN 388088-84-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-7-(methylsulfonyl)- (CA INDEX NAME)



IT 388088-67-3P 388088-68-4P 388088-69-5P
388088-72-0P 388088-76-4P 388088-78-6P
388088-80-0P 388088-82-2P 388088-85-5P
388088-87-7P 388088-88-8P 388088-89-9P
388088-90-2P 388088-91-3P 388088-92-4P
388088-93-5P 388088-94-6P 388088-95-7P
388088-96-8P 388088-97-9P 388088-98-0P
388088-99-1P 388089-00-7P 388089-01-8P
388089-02-9P 388089-03-0P 388089-04-1P
388089-05-2P 388089-06-3P 388089-07-4P
388089-08-5P 388089-09-6P 388089-10-9P
388089-12-1P 388089-13-2P 388089-14-3P
388089-15-4P 388089-16-5P 388089-17-6P
388089-19-8P 388089-21-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused thienopyrimidines for treatment of cerebral ischemia)
RN 388088-67-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 388088-68-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-69-5 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-72-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-[4-[4-(1-isoquinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 388088-76-4 CAPLUS
CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-78-6 CAPLUS
CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-80-0 CAPLUS
CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-, 7-oxide (CA INDEX NAME)



RN 388088-82-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-85-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-cyclopropyl-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-87-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,7-dione, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-88-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 388088-89-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 388088-90-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-hydroxyphenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 388088-91-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 388088-92-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-93-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-94-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[4-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 388088-95-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-96-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 388088-97-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-[4-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 388088-98-0 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 388088-99-1 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[3-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 388089-00-7 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 388089-01-8 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-

(1-naphthalenyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 388089-02-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-03-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 6,7-dihydro-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-04-1 CAPLUS
CN Benzenesulfonamide, 4-fluoro-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 388089-05-2 CAPLUS
CN Benzenesulfonamide, 3-methyl-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 388089-06-3 CAPLUS
CN Benzenesulfonamide, 4-nitro-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 388089-07-4 CAPLUS
CN Benzenesulfonamide, N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 388089-08-5 CAPLUS
CN Benzenesulfonamide, 4-amino-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 388089-09-6 CAPLUS
CN Benzenesulfonamide, 3-nitro-N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 388089-10-9 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[2-[3,5,6,8-tetrahydro-4-oxo-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 388089-12-1 CAPLUS
CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 388089-11-0
CMF C24 H25 N5 O2 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 388089-13-2 CAPLUS

CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-14-3 CAPLUS
CN 4H-Thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]-, 7-oxide (CA INDEX NAME)



RN 388089-15-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-16-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(methylsulfonyl)-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-17-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-7-(phenylsulfonyl)- (CA INDEX NAME)



RN 388089-19-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-fluorophenyl)sulfonyl]-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388089-21-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

IT 385821-46-5 388088-74-2 521913-49-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused thienopyrimidines for treatment of cerebral ischemia)

RN 385821-46-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(8-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-74-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 3-(4-chlorobutyl)-6,7-dihydro- (CA INDEX NAME)



RN 521913-49-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



IT 388088-51-5P 388088-52-6P 388088-55-9P
388088-56-0P 388088-57-1P 388088-86-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused thienopyrimidines for treatment of cerebral ischemia)

RN 388088-51-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-hydroxyethyl)- (CA INDEX NAME)



RN 388088-52-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 388088-55-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione, 3-(2-chloroethyl)-6,7-dihydro- (CA INDEX NAME)



RN 388088-56-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-57-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 388088-86-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(4H)-carboxaldehyde, 3,5,6,8-tetrahydro-3-[2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl]-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:82586 CAPLUS
DOCUMENT NUMBER: 135:101920
TITLE: Thrombolysis by thienopyridines and their congeners
AUTHOR(S): Gryglewski, R. J.; Dupin, J. P.; Uracz, W.; Swies, J.; Madej, J.; Hou, G.; Gravier, D.; Casadebaig, F.
CORPORATE SOURCE: Chair of Pharmacology, Medical College of Jagiellonian University Cracow, Pol.
SOURCE: Journal of Physiology and Pharmacology (2000), 51(4, Pt. 1), 683-693
CODEN: JPHPEI; ISSN: 0867-5910
PUBLISHER: Polish Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We propose that anti-platelet thienopyridines, such as ticlopidine or clopidogrel, are thrombolytic owing to endothelial release of prostacyclin (PGI2) and tissue plasminogen activator (t-PA). In this study we used anesthetized Wistar rats with extracorporeal circulation in which thrombi that adhered to a strip of collagen were superfused with arterial blood. Weight of thrombi was continuously monitored. When administered i.v., clopidogrel or its R enantiomer deprived of anti-platelet action, both at doses of 3 mg kg-1, produced lost in weight of thrombi by 14.1±1.3% or 16.0±1.4% (n = 9), and at doses 10 mg kg-1 by 28.3±2.3% or 30.4±1.9% (n = 8), resp. Maximum of thrombolysis occurred 30-45 min following the drug administration. Ticlopidine at a dose of 30 mg kg-1 reduced weight of thrombi by 33.7±1.7% (n = 32). Thrombolytic action of ticlopidine was accompanied by a rise in 6-keto-PGF1α blood levels from 0.42±0.10 to 1.58±0.29 ng ml-1 and t-PA antigen plasma levels from 4.70±1.00 to 12.90±1.15 ng ml-1 (n = 7). Five out of eleven tested thienopyridine congeners with pyrimidine or pyrimidinone instead of pyridine rings had thrombolytic potencies similar to that of clopidogrel (ED30s at a range of 6.2-11.4 mg kg-1). A substantial increase in thrombolytic potency (ED30s at a range of 0.3-2.1 mg kg-1) was observed for congeners in which thienyl ring was condensed with an addnl. cyclopentyl, cyclohexyl or cycloheptyl structures or in which thienopyridine complex was replaced for a pyridopyrimidine one. We claim that thienopyridines, independently of their delayed anti-platelet action, do produce immediate thrombolysis in vivo. This new activity emulates capacity of their native, non-metabolized mols. to release prostacyclin and tissue plasminogen activator. We have also shown that structural changes in mols. of thienopyridines may intensify their thrombolytic potency.

IT 40277-27-8 146070-98-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thrombolysis by thienopyridines and congeners in relation to prostacyclin and tissue plasminogen activator release)

RN 40277-27-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 146070-98-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(2-chlorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



IT 202656-47-1P 202656-48-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(thrombolysis by thienopyridines and congeners in relation to prostacyclin and tissue plasminogen activator release)
RN 202656-47-1 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 202656-48-2 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-3-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:475949 CAPLUS
DOCUMENT NUMBER: 133:99584
TITLE: Use of 5-HT5 receptor ligands for the treatment of neurodegenerative and neuropsychiatric diseases, and screening method
INVENTOR(S): Garcia-Ladona, Francisco Javi; Szabo, Laszlo; Steiner, Gerd; Hofmann, Hans-Peter
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19900673	A1	20000713	DE 1999-19900673	19990111
CA 2359357	A1	20000720	CA 2000-2359357	20000111
WO 2000041696	A1	20000720	WO 2000-EP143	20000111
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1143975	A1	20011017	EP 2000-904894	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534466	T	20021015	JP 2000-593307	20000111
MX 2001PA06987	A	20020918	MX 2001-PA6987	20010710
US 6750221	B1	20040615	US 2001-889157	20010711
US 20040202656	A1	20041014	US 2004-836349	20040503

PRIORITY APPLN. INFO.:		
DE 1999-19900673	A	19990111
WO 2000-EP143	W	20000111
US 2001-889157	A3	20010711

AB The invention discloses the use of 5-HT5 receptor ligands for the treatment of neurodegenerative and/or neuropsychiatric diseases, which in particular can occur with cerebral ischemia, stroke, epilepsy, and attacks generally, chronic schizophrenia, other psychotic illnesses, dementia, in particular Alzheimer dementia, demyelinating diseases, in particular multiple sclerosis, and brain tumors. The invention also discloses methods for the identification and characterization of such ligands, in particular in the form of screening methods.

IT 217487-25-7P 281657-26-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-HT5 receptor ligand for treatment of neurodegenerative and neuropsychiatric disease, and screening method)
RN 217487-25-7 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-26-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L7 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:475944 CAPLUS
DOCUMENT NUMBER: 133:89541
TITLE: Preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia
INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Lubisch, Wilfried; Holzenkamp, Uta; Starck, Dorothea; Knopp, Monika; Szabo, Laszlo; Emling, Franz; Garcia-Ladona, Francisco Javi; Hofmann, Hans-Peter; Unger, Liliane
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19900545	A1	20000713	DE 1999-19900545	19990111
CA 2359253	A1	20000720	CA 1999-2359253	19991224
WO 2000041695	A1	20000720	WO 1999-EP10369	19991224
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140096	A1	20011010	EP 1999-967980	19991224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916887	A	20011120	BR 1999-16887	19991224
TR 200102008	T2	20011221	TR 2001-2008	19991224
HU 2002001149	A2	20020729	HU 2002-1149	19991224
HU 2002001149	A3	20030728		
JP 2002534465	T	20021015	JP 2000-593306	19991224
NZ 512767	A	20030530	NZ 1999-512767	19991224
ZA 2001005475	A	20021003	ZA 2001-5475	20010703
MX 2001PA06967	A	20020410	MX 2001-PA6967	20010709
NO 2001003409	A	20010830	NO 2001-3409	20010710
BG 105689	A	20020228	BG 2001-105689	20010710
US 6387912	B1	20020514	US 2001-889162	20010711

PRIORITY APPLN. INFO.: DE 1999-19900545 A 19990111
WO 1999-EP10369 W 19991224
OTHER SOURCE(S): MARPAT 133:89541
GI



I



II

AB Thienopyrimidines I [A = O, NH; B = H, Me; D = Me, E = (un)substituted CONH2; DE = CH2CH2NR1CH2, CH2NR1CH2, CH2NR1CH2CH2; YZ = (CH2)mN, (CH2)mCH, CH2CH:C; m = 1-3; R1 = H, alkyl, Ac, Bz, (un)substituted phenylalkyl; R2 = (un)substituted Ph, pyridyl, pyrimidinyl, pyrazinyl] were prepared for use in the treatment of cerebral ischemia and stroke (no data). Thus, the pyrido[4',3':4,5]thieno[2,3-d]pyrimidine II was prepared from the 2-ethoxymethylenamino analog and 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine.

IT 281657-06-5 281657-08-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)

RN 281657-06-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloro-1-methylethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-08-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloropropyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



IT 217487-50-8P 217487-52-0P 220415-18-9P
220415-22-5P 220415-23-6P 281657-00-9P
281657-01-0P 281657-02-1P 281657-11-2P
281657-13-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)

RN 217487-50-8 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-(2-hydroxyethyl)- (CA INDEX NAME)



RN 217487-52-0 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-6-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 220415-18-9 CAPLUS
CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 220415-22-5 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-(2-hydroxyethyl)-4-oxo-, ethyl ester (CA INDEX NAME)



RN 220415-23-6 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-(2-chloroethyl)-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 281657-00-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-hydroxyethyl)-7-methyl- (CA INDEX NAME)



RN 281657-01-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-02-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-hydroxypropyl)-7-methyl- (CA INDEX NAME)



RN 281657-11-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-13-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



IT 220415-24-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)
RN 220415-24-7 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



IT 204385-90-0P 204385-94-4P 204386-13-0P
204386-15-2P 204386-34-5P 204386-46-9P
204386-57-2P 217487-11-1P 217487-16-6P
217487-22-4P 217487-25-7P 217487-30-4P
217487-33-7P 217487-36-0P 217487-38-2P
220415-16-7P 220415-19-0P 281656-84-6P
281657-03-2P 281657-04-3P 281657-05-4P
281657-07-6P 281657-09-8P 281657-14-5P
281657-18-9P 281657-19-0P 281657-20-3P
281657-21-4P 281657-22-5P 281657-23-6P
281657-24-7P 281657-25-8P 281657-26-9P
281657-27-0P 281657-29-2P 281657-30-5P
281657-31-6P 281657-32-7P 281657-33-8P
281657-34-9P 281657-38-3P 281657-39-4P
281657-40-7P 281657-41-8P 281657-42-9P
281657-43-0P 281657-44-1P 281657-45-2P
281657-46-3P 281657-47-4P 281657-48-5P
281657-49-6P 281657-50-9P 281657-51-0P
281657-52-1P 281657-53-2P 281657-54-3P
281657-55-4P 281657-56-5P 281657-57-6P
281657-58-7P 281657-59-8P 281657-60-1P
281657-61-2P 281657-62-3P 281657-63-4P
281657-64-5P 281657-65-6P 281657-66-7P
281657-67-8P 281657-68-9P 281657-69-0P

281657-70-3P 281657-71-4P 281657-72-5P
281657-73-6P 281657-74-7P 281657-75-8P
281657-76-9P 281657-77-0P 281657-78-1P
281657-79-2P 281657-80-5P 281657-81-6P
281657-82-7P 281657-83-8P 281657-84-9P
281657-85-0P 281657-86-1P 281657-87-2P
281657-88-3P 281657-90-7P 281657-91-8P
281657-92-9P 281657-93-0P 281657-94-1P
281657-95-2P 281657-96-3P 281657-99-6P
281658-00-2P 281658-01-3P 281658-03-5P
281658-04-6P 281658-05-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)

RN 204385-90-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 204385-94-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 204386-13-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-(phenylmethyl)- (CA INDEX

NAME)



RN 204386-15-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(phenylmethyl)-3-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 204386-34-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 204386-46-9 CAPLUS
CN Benzonitrile, 2-[4-[3-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)propyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 204386-57-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(phenylmethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 217487-11-1 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 217487-16-6 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-

tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 217487-22-4 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methyl-1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 217487-25-7 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 217487-30-4 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-6-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 217487-33-7 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 217487-36-0 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 217487-38-2 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-3-[2-[hexahydro-4-(1-naphthalenyl)-1H-1,4-diazepin-1-yl]ethyl]-5,6,7,8-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 220415-16-7 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



RN 220415-19-0 CAPLUS
CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 6-ethyl-3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281656-84-6 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1-naphthalenyl)-1(2H)-pyridinyl]ethyl]-6-ethyl-5,6,7,8-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 281657-03-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-04-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-05-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[1-methyl-2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-07-6 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-09-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2,7-dimethyl- (CA INDEX NAME)



RN 281657-14-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-[2-(1-naphthalenyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-18-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-19-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-20-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,4-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-21-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,6-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-22-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,3-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA

INDEX NAME)



RN 281657-23-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,4-dimethylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 281657-24-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,5-dichlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-25-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,4-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-26-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-27-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-29-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-30-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,5-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-31-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-methoxy[1,1'-biphenyl]-3-yl)-1-piperazinyl]ethyl]-7-methyl- (CA INDEX NAME)



RN 281657-32-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(2-

methoxyphenyl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-33-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-hydroxyphenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-34-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-38-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-39-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-40-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,4-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-41-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[3-[4-(1-naphthalenyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-42-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)



RN 281657-43-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-44-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[3-[4-(2-methyl-1-naphthalenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-45-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(3,5-dichloro-2-methoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-46-3 CAPLUS
CN Benzonitrile, 2-[4-[2-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 281657-47-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 281657-48-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-49-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]ethyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-50-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-51-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-(4-pyrazinyl-1-piperazinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-52-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-53-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,3-dihydro-1H-inden-1-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-54-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-

[4-(2-methoxy-5-methyl-4-nitrophenyl)-1-piperazinyl]ethyl]-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-55-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(4-isoquinolinyl)-1-piperazinyl]ethyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-56-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4-chloro-2-methoxy-5-methylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-57-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,4-dimethoxyphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-58-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(4-quinazolinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-59-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-60-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-61-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(1-methylethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-62-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-[(4-nitrophenyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-63-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-64-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(2-phenylethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-65-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(4-oxo-4-phenylbutyl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-66-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-aminophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 281657-67-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(3-phenylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-68-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-7-(3-phenylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-69-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-70-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[2-(4-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-71-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-7-(2-phenylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-72-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-hydroxyphenyl)ethyl]-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-73-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[2-(4-chlorophenyl)ethyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-74-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-[2-(1-naphthalenyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-75-8 CAPLUS
CN Benzamide, N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-76-9 CAPLUS
CN Benzamide, N-[2-[3,5,6,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-77-0 CAPLUS
CN Benzamide, N-[3-[3,5,6,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-78-1 CAPLUS
CN Benzamide, N-[3-[3,5,6,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-79-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(4-phenylbutyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-80-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-7-(4-phenylbutyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-81-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-82-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 3 HCl

PAGE 1-B

— OMe

RN 281657-83-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(1-naphthalenyl)-1-piperazinyl]propyl]-7-(2-phenylethyl)- (CA INDEX NAME)



RN 281657-84-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(2-phenylethyl)-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-85-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(2-phenylethyl)-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-86-1 CAPLUS
CN Benzamide, N-[3-[3,5,6,8-tetrahydro-4-oxo-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(4H)-yl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-87-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(4-phenylbutyl)-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 281657-88-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-[2-(4-methoxyphenyl)ethyl]-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OMe

RN 281657-90-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-acetyl-5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-91-8 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-benzoyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 281657-92-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-benzoyl-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-93-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-benzoyl-5,6,7,8-tetrahydro-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 281657-94-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-

[4-(2-methoxyphenyl)-1-piperazinyl]-1-methylethyl]-7-methyl- (CA INDEX NAME)



RN 281657-95-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[1-methyl-2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 281657-96-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-1-methylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 281657-99-6 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid,

3-[2-[hexahydro-4-(1-naphthalenyl)-1H-1,4-diazepin-1-yl]ethyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 281658-00-2 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-4-oxo-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-, ethyl ester (CA INDEX NAME)



RN 281658-01-3 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



RN 281658-03-5 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]propyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 281658-04-6 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-[3-[4-(2-cyanophenyl)-1-piperazinyl]propyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 281658-05-7 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-[2-[4-(2,3-dihydro-1H-inden-4-yl)-1-piperazinyl]ethyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



L7 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:10812 CAPLUS
DOCUMENT NUMBER: 132:222501
TITLE: Action of amines and hydrazines on N-(3-carbethoxy-2-thienyl)iminoethers: synthesis of thieno[2-3-d]pyrimidin-4(3H)-ones
AUTHOR(S): Dridi, K.; El Efrit, M. L.; Zantour, H.
CORPORATE SOURCE: Lab. Synthese Organique, Campus Universitaire, Tunis, Tunisia
SOURCE: Journal de la Societe Chimique de Tunisie (1999), 4(5), 387-392
CODEN: JSCTDP; ISSN: 0253-1208
PUBLISHER: Societe Chimique de Tunisie
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 132:222501
GI



AB N-(3-carbethoxy-2-thienyl)iminoethers [I; R1 = Ph, Me; R2 = H, Me; R1R2 = (CH2)4; R3 = H, Me, Et], obtained from 2-amino-3-carbethoxy-thiophenes, react with primary amines and hydrazines to give thieno[2,3-d]pyrimidin-4(3H)-ones (II; same R1, R2, R3; R4 = OH, benzyl, Ph, CHMePh, NH2, NHPh, NHMe, etc.). The reaction proceeds via intermediate amidines, which were isolated.
IT 40277-27-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(cyclocondensation of N-(3-carbethoxy-2-thienyl)iminoethers with amines and hydrazines)
RN 40277-27-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:116653 CAPLUS
DOCUMENT NUMBER: 130:168389
TITLE: Preparation of 3,4,5,7-tetrahydropyrrolo[3',4':4,5]thieno[2,3-d]pyrimidines as selective 5-HT1B and 5-HT1A antagonists.
INVENTOR(S): Steiner, Gerd; Dullweber, Uta; Starck, Dorothea; Bach, Alfred; Wicke, Karsten; Teschendorf, Hans-Juergen; Garcia-Ladona, Francisco-javi D.; Emling, Franz
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19734444	A1	19990211	DE 1997-19734444	19970808
CA 2300391	A1	19990218	CA 1998-2300391	19980723
WO 9907711	A1	19990218	WO 1998-EP4633	19980723
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9890683	A	19990301	AU 1998-90683	19980723
AU 749539	B2	20020627		
EP 1003752	A1	20000531	EP 1998-942610	19980723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9811091	A	20000912	BR 1998-11091	19980723
TR 200000371	T2	20001121	TR 2000-371	19980723
NZ 502657	A	20010629	NZ 1998-502657	19980723
JP 2001512734	T	20010828	JP 2000-506214	19980723
HU 2001001311	A2	20010928	HU 2001-1311	19980723
HU 2001001311	A3	20021028		
CZ 290678	B6	20020911	CZ 2000-462	19980723
ZA 9807114	A	20000207	ZA 1998-7114	19980807
TW 513435	B	20021211	TW 1998-87113048	19980807
IN 1998MA01792	A	20050304	IN 1998-MA1792	19980807
MX 200001119	A	20001108	MX 2000-1119	20000201
NO 2000000605	A	20000207	NO 2000-605	20000207
US 6355647	B1	20020312	US 2000-485188	20000207
BG 104151	A	20001031	BG 2000-104151	20000210

PRIORITY APPLN. INFO.: DE 1997-19734444 A 19970808
WO 1998-EP4633 W 19980723
OTHER SOURCE(S): MARPAT 130:168389
GI



I

AB Title compds. [I; R1 = H, alkyl, Ac, (substituted) phenylalkyl, alkylcarbonyl; R2 = (substituted) Ph, pyridyl, pyrimidinyl, pyrazinyl; A = NHY, O; Y = CH2, CH2CH2, (CH2)3, CH2CH; Z = N, C, CH; n = 2-4; dotted line = optional double bond], were prepared as antidepressants (no data). Thus, 2-ethoxymethyleneamino-3,5-dicarboethoxy-4,6-dihydrothieno[3,2-c]pyrrole (preparation given) was refluxed with 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine in EtOH 3,4,5,7-tetrahydro-6-carboethoxy-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one.

IT 220415-16-7P 220415-17-8P 220415-18-9P
220415-19-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydropyrrolothienopyrimidines as selective 5-HT1B and 5-HT1A antagonists)

RN 220415-16-7 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



RN 220415-17-8 CAPLUS

CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-[2-[hexahydro-4-(1-naphthalenyl)-1H-1,4-diazepin-1-yl]ethyl]-3,4,5,7-tetrahydro-4-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 220415-18-9 CAPLUS
CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 220415-19-0 CAPLUS
CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 6-ethyl-3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 220415-24-7 220415-25-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetrahydropyrrolothienopyrimidines as selective 5-HT1B and 5-HT1A antagonists)

RN 220415-24-7 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



RN 220415-25-8 CAPLUS
CN 4H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



IT 220415-22-5P 220415-23-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydropyrrolothienopyrimidines as selective 5-HT1B and 5-HT1A antagonists)

RN 220415-22-5 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3,4,5,7-tetrahydro-3-(2-hydroxyethyl)-4-oxo-, ethyl ester (CA INDEX NAME)



RN 220415-23-6 CAPLUS
CN 6H-Pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine-6-carboxylic acid, 3-(2-chloroethyl)-3,4,5,7-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



L7 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:7999 CAPLUS
DOCUMENT NUMBER: 130:52437
TITLE: Preparation of piperazinylethylpyridothienopyrimidones as antidepressants.
INVENTOR(S): Steiner, Gerd; Dullweber, Uta; Starck, Dorothea; Bach, Alfred; Wicke, Karsten; Teschendorf, Hans-jurgen; Garcia-Ladona, Francisco-Javier; Emling, Franz
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856793	A1	19981217	WO 1998-EP3231	19980529
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19724979	A1	19981217	DE 1997-19724979	19970613
CA 2293440	A1	19981217	CA 1998-2293440	19980529
AU 9885357	A	19981230	AU 1998-85357	19980529
AU 748697	B2	20020613		
TR 9903061	T2	20000721	TR 1999-3061	19980529
EP 1023296	A1	20000802	EP 1998-936299	19980529
EP 1023296	B1	20031217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9810008	A	20000919	BR 1998-10008	19980529
HU 2000002736	A2	20010228	HU 2000-2736	19980529
HU 2000002736	A3	20010428		
NZ 502237	A	20010831	NZ 1998-502237	19980529
JP 2002504104	T	20020205	JP 1999-501459	19980529
AT 256686	T	20040115	AT 1998-936299	19980529
ES 2215312	T3	20041001	ES 1998-936299	19980529
TW 479059	B	20020311	TW 1998-87108721	19980603
ZA 9805120	A	19991213	ZA 1998-5120	19980612
MX 9910621	A	20000430	MX 1999-10621	19991118
NO 9906045	A	19991208	NO 1999-6045	19991208
US 6159981	A	20001212	US 1999-445178	19991208
PRIORITY APPLN. INFO.:			DE 1997-19724979 A	19970613
			WO 1998-EP3231 W	19980529

OTHER SOURCE(S): MARPAT 130:52437
GI



I

AB Title compds. [I; R1 = H, alkyl, Ac, (substituted) phenylalkyl, phenylalkanonyl; R2 = (substituted) (benzoanellated) Ph, pyridyl, pyrimidinyl, pyrazinyl; A = NH, O; Y = CH2, CH2CH2, CH2CH2CH2, CH2CH; Z = N, C, CH; the bond between Y and Z can = double bond; n = 2, 3, 4], were prepared as antidepressants (no data). I show a high level of affinity for 5-HT1B, 5-HT1D and 5-HT1A receptors, and some I inhibit serotonin reuptake. Thus, 2-ethoxymethyleneamino-3-ethoxycarbonyl-5-ethyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (preparation given) and 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine were refluxed in EtOH to give 48% 3,4,5,6,7,8-hexahydro-6-ethyl-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4-one hydrochloride.

IT 217487-11-1P 217487-16-6P 217487-22-4P
217487-25-7P 217487-30-4P 217487-33-7P
217487-36-0P 217487-38-2P 217487-40-6P
217487-43-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinylethylpyridothienopyrimidones as antidepressants)

RN 217487-11-1 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 217487-16-6 CAPLUS

CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 217487-22-4 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(2-methyl-1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 217487-25-7 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(1-naphthalenyl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 217487-30-4 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-6-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 217487-33-7 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 217487-36-0 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[2-[4-(5,6,7,8-tetrahydro-1-naphthalenyl)-1-piperazinyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 217487-38-2 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-3-[2-[hexahydro-4-(1-naphthalenyl)-1H-1,4-diazepin-1-yl]ethyl]-5,6,7,8-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 217487-40-6 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1-naphthalenyl)-1(2H)-pyridinyl]ethyl]-6-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 217487-43-9 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-[3-(4-phenyl-1-piperidinyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



IT 217487-50-8P 217487-52-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazinylethylpyridothienopyrimidones as antidepressants)

RN 217487-50-8 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 6-ethyl-5,6,7,8-tetrahydro-3-(2-hydroxyethyl)- (CA INDEX NAME)



RN 217487-52-0 CAPLUS
CN Pyrido[3',4':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-chloroethyl)-6-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:184124 CAPLUS
DOCUMENT NUMBER: 128:217381
TITLE: Preparation of 3-substituted pyrido(4',3':4,5)thieno[2,3-d]pyrimidines as 5-HT1A receptor antagonists and serotonin reuptake inhibitors
INVENTOR(S): Steiner, Gerd; Lubisch, Wilfried; Bach, Alfred; Emling, Franz; Wicke, Karsten; Teschendorf, Hans-Juergen; Behl, Berthold; Kerrigan, Frank; Cheetham, Sharon
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19636769	A1	19980312	DE 1996-19636769	19960910
CA 2265509	A1	19980319	CA 1997-2265509	19970822
WO 9811110	A1	19980319	WO 1997-EP4593	19970822
W: AL, AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9742071	A	19980402	AU 1997-42071	19970822
AU 736678	B2	20010802		
EP 927184	A1	19990707	EP 1997-940118	19970822
EP 927184	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9711724	A	19990824	BR 1997-11724	19970822
CN 1230962	A	19991006	CN 1997-197765	19970822
HU 9904107	A2	20000528	HU 1999-4107	19970822
HU 9904107	A3	20011029		
NZ 334350	A	20000728	NZ 1997-334350	19970822
JP 2001500138	T	20010109	JP 1998-513191	19970822
CZ 288896	B6	20010912	CZ 1999-759	19970822
SK 283039	B6	20030204	SK 1999-230	19970822
RU 2198888	C2	20030220	RU 1999-106781	19970822
AT 252587	T	20031115	AT 1997-940118	19970822
PT 927184	T	20040331	PT 1997-940118	19970822
ES 2210570	T3	20040701	ES 1997-940118	19970822
TW 480264	B	20020321	TW 1997-86112642	19970902
IN 1997MA01971	A	20050304	IN 1997-MA1971	19970905
ZA 9708081	A	19990309	ZA 1997-8081	19970909
BG 63602	B1	20020628	BG 1999-103122	19990127
NO 9901132	A	19990309	NO 1999-1132	19990309
KR 2000035987	A	20000626	KR 1999-701939	19990309
US 6222034	B1	20010424	US 1999-254449	19990310
CN 1332168	A	20020123	CN 2001-116979	20010518

PRIORITY APPLN. INFO.: DE 1996-19636769 A 19960910
WO 1997-EP4593 W 19970822
OTHER SOURCE(S): CASREACT 128:217381; MARPAT 128:217381
GI



I



II



III

AB The title compds. [I; R1 = H, C1-4 alkyl, Ac, (un)substituted Ph-C1-4 alkyl, etc.; R2 = (un)substituted Ph, pyridyl, pyrimidinyl, pyrazinyl, etc.; A = NH, O; X = N, CH; Y = CH2, CH2CH2, CH2CH; Z = N, C, CH; YZ bond can be double bond; n = 1-4], selective 5HT1B and 5HT1A antagonists and serotonin reuptake inhibitors (no data) useful for treatment of depressions and related diseases, were prepared by cyclocondensation of tetrahydrothienopyridines (II; R1 as defined above, R3 = cyano, C1-3 alkyl carboxylate group; R4 = C1-3 alkyl) with primary amines (III; R2, X, Y, Z, n as defined above). For example, refluxing 46.0 g 2-amino-3-cyano-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine in 250 mL HC(OEt)3 containing 3.5 mL Ac2O for 4 h under N gave 45.4 g 2-ethoxymethyleneamino-3-cyano-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine (m. 88-89°). This (3.0 g) was refluxed for 3 h with 3.3 g 1-(2-aminoethyl)-4-(o-methoxyphenyl)piperazine in 60 mL EtOH and the product salified to give 3.6 g 3,4,5,6,7,8-hexahydro-7-methyl-3-[2-(4-(o-methoxyphenyl)-1-piperazino)ethyl]pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-imine-3HCl (decomposition 282-284°).

IT 204385-90-0P 204385-94-4P 204386-13-0P
204386-15-2P 204386-34-5P 204386-46-9P
204386-57-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridothienopyrimidines as 5-HT1A receptor antagonists and serotonin reuptake inhibitors)

RN 204385-90-0 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 204385-94-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 204386-13-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-(phenylmethyl)- (CA INDEX NAME)



RN 204386-15-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(phenylmethyl)-3-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 204386-34-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 204386-46-9 CAPLUS
CN Benzonitrile, 2-[4-[3-(5,6,7,8-tetrahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)propyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 204386-57-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-7-(phenylmethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

IT 204385-92-2P 204385-97-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridothienopyrimidines as 5-HT1A receptor antagonists and serotonin reuptake inhibitors)

RN 204385-92-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 204385-97-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-7-methyl- (CA INDEX NAME)



L7 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:66092 CAPLUS
DOCUMENT NUMBER: 128:149581
TITLE: Heterocyclic compounds with thrombolytic activity, preparation, and use for treating thrombosis
INVENTOR(S): Dupin, Jean-Pierre; Gryglewsky, Richard; Gravier, Denis; Casadebaig, Francoise; Hou, Genevieve
PATENT ASSIGNEE(S): Dupin, Jean-Pierre, Fr.; Gryglewsky, Richard; Gravier, Denis; Casadebaig, Francoise; Hou, Genevieve
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9802162	A1	19980122	WO 1997-FR1278	19970711
W: AU, CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2750862	A1	19980116	FR 1996-8969	19960712
FR 2750862	B1	19981016		
CA 2260965	A1	19980122	CA 1997-2260965	19970711
AU 9736968	A	19980209	AU 1997-36968	19970711
EP 912180	A1	19990506	EP 1997-933710	19970711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1228701	A	19990915	CN 1997-197579	19970711
JP 2000514447	T	20001031	JP 1998-505674	19970711
PRIORITY APPLN. INFO.:			FR 1996-8969 A	19960712
			WO 1997-FR1278 W	19970711

OTHER SOURCE(S): MARPAT 128:149581
AB Heterocyclic compds. (Markush included) are provided for the preparation of medicines for treating thrombosis. Preparation and biol. activity of e.g. 3-benzyl-1,2-dihydrocyclohepta[b]thieno[2,3-d]pyrimidin-4(3H)-one are presented.
IT 202656-47-1P 202656-48-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; heterocyclic compds. with thrombolytic activity, preparation, and use for treating thrombosis)
RN 202656-47-1 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 202656-48-2 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-3-

(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:984855 CAPLUS
DOCUMENT NUMBER: 124:175999
ORIGINAL REFERENCE NO.: 124:32639a,32642a
TITLE: Synthesis and effect of gamma radiation on some sulfur-containing 3-substituted-4-oxo-2,4,5,6,7,8-hexahydrobenzo[b]thieno[2,3-d]pyrimidines of biological interest
AUTHOR(S): Ghorab, M. M.; Abdel Hamide, S. G.
CORPORATE SOURCE: National Center for Radiation Research, Technology Atomic Energy Authority, Cairo, Egypt
SOURCE: Phosphorus, Sulfur and Silicon and the Related Elements (1995), 106(1-4), 9-20
CODEN: PSSLEC; ISSN: 1042-6507
PUBLISHER: Gordon & Breach
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:175999
GI



I

Q =



AB Condensation of 4-oxo-3,4,5,6,7,8-hexahydrobenzo[b]thienopyrimidine [I; R = H] with allyl bromide or Et chloroacetate gave I [R = allyl, ethoxycarbonylmethyl]. Interaction of the ester derivative I [R = ethoxycarbonylmethyl] with hydrazine hydrate furnished the hydrazide derivative I [R = CH2-CO-NHNH2] which was used as starting material for the synthesis of pyrazoles, oxadiazoles, thiosemicarbazide and hydrazone derivs., I [R = substituted pyrazolylcarbonylmethyl, substituted oxadiazolylmethyl, CH2-CO-NH-NH-C(S)-NH-R1 where R1 = Me, Et, phenyl; CH2-CO-NH-N:CH-R2 where R2 = 4-pyridinyl, 2-thienyl, p-R3-C6H4 where R3 = H, Me, NO2, fluoro, chloro, Br] resp. Cyclodehydration of thiosemicarbazide derivative I [R = CH2-CO-NH-NH-C(S)-NH-Ph] with sodium hydroxide resulted in the formation of the corresponding N-phenylmercaptotriazole derivative The thiazolidinones I [R = Q where R4 = Ph, p-tolyl, 4-pyridinyl, 2-thienyl] were obtained through the interaction of the hydrazone derivs. I [R = CH2-CO-NH-N:CH-R2] with mercaptoacetic acid. The obtained compds. have been characterized on the basis of their spectral (IR, PMR and Mass) data and elemental anal. Most of these compds. have been found to exhibit good antibacterial and antifungal activities. The stability of some biol. active compds. towards gamma radiation have been investigated.

IT 40277-49-4P 162884-74-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and effect of gamma radiation on sulfur-containing 3-substituted oxohydrobenzo[b]thieno[d]pyrimidines)

RN 40277-49-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 162884-74-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, hydrazide (CA INDEX NAME)



IT 162884-80-2P 162884-82-4P 162884-84-6P
162884-85-7P 162884-86-8P 162884-87-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and effect of gamma radiation on sulfur-containing 3-substituted oxohydrobenzo[b]thieno[d]pyrimidines)
RN 162884-80-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(methylamino)thioxomethyl]hydrazide (CA INDEX NAME)



RN 162884-82-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(phenylamino)thioxomethyl]hydrazide (CA INDEX NAME)



RN 162884-84-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 162884-85-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-methylphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-86-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-87-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-fluorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



IT 40277-45-0P 162884-75-5P 162884-76-6P
162884-77-7P 162884-78-8P 162884-79-9P
162884-81-3P 162884-83-5P 162884-88-0P
162884-89-1P 162884-90-4P 162884-91-5P
173679-84-0P 173679-87-3P 173679-88-4P
173679-89-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and effect of gamma radiation on sulfur-containing 3-substituted oxohydrobenzo[b]thieno[d]pyrimidines)

RN 40277-45-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 162884-75-5 CAPLUS
CN 1H-Pyrazole, 3,5-dimethyl-1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 162884-76-6 CAPLUS
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 162884-77-7 CAPLUS
CN 3,5-Pyrazolidinedione, 1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 162884-78-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]- (CA INDEX NAME)



RN 162884-79-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-5-thioxo-1,3,4-oxadiazol-2-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 162884-81-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(ethylamino)thioxomethyl]hydrazide (CA INDEX NAME)



RN 162884-83-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 162884-88-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-89-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-bromophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-90-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (4-pyridinylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 162884-91-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (2-thienylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 173679-84-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-(5-oxo-2-phenyl-3-thiazolidinyl)- (CA INDEX NAME)



RN 173679-87-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-N-[2-(4-methylphenyl)-5-oxo-3-thiazolidinyl]-4-oxo- (CA INDEX NAME)



RN 173679-88-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-[5-oxo-2-(4-pyridinyl)-3-thiazolidinyl]- (CA INDEX NAME)



RN 173679-89-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-[5-oxo-2-(2-thienyl)-3-thiazolidinyl]- (CA INDEX NAME)



L7 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:402279 CAPLUS
DOCUMENT NUMBER: 122:314510
ORIGINAL REFERENCE NO.: 122:57197a,57200a
TITLE: Synthesis of some new 3-substituted-4-oxo-3,4,5,6,7,8-hexahydrobenzo[b]thieno [2,3-d]pyrimidines of biological interest
AUTHOR(S): Ghorab, M. M.; Hamide, S. G. Abdel
CORPORATE SOURCE: National Center Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt
SOURCE: Indian Journal of Heterocyclic Chemistry (1994), 4(2), 103-6
CODEN: IJCHEI; ISSN: 0971-1627
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Condensation of 4-oxo-3,4,5,6,7,8-hexahydrobenzo[b]thieno[2,3-d]pyrimidine with Et chloroacetate gave (I). Interaction of I with hydrazine hydrate furnished the hydrazide, which was used for the synthesis of pyrazoles, oxadiazoles, thiosemicarbazide and hydrazone derivs. Cyclodehydration of the thiosemicarbazide derivative with sodium hydroxide resulted in the formation of a N-phenylmercaptotriazole derivative Most of these compds. have been found to exhibit promising antibacterial and antifungal activities.

IT 40277-49-4P 162884-74-4P 162884-82-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of benzothienopyrimidines as bactericides and fungicides)

RN 40277-49-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 162884-74-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, hydrazide (CA INDEX NAME)



RN 162884-82-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(phenylamino)thioxomethyl]hydrazide (CA INDEX NAME)



IT 162884-75-5P 162884-76-6P 162884-77-7P
162884-78-8P 162884-79-9P 162884-80-2P
162884-81-3P 162884-83-5P 162884-84-6P
162884-85-7P 162884-86-8P 162884-87-9P
162884-88-0P 162884-89-1P 162884-90-4P
162884-91-5P 162884-92-6P 162884-93-7P
162884-94-8P 162884-95-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of benzothienopyrimidines as bactericides and fungicides)

RN 162884-75-5 CAPLUS
CN 1H-Pyrazole, 3,5-dimethyl-1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 162884-76-6 CAPLUS
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 162884-77-7 CAPLUS
CN 3,5-Pyrazolidinedione, 1-[(5,6,7,8-tetrahydro-4-oxo[1]benzothieno[2,3-d]pyrimidin-3(4H)-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 162884-78-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]- (CA INDEX NAME)



RN 162884-79-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-5-thioxo-1,3,4-oxadiazol-2-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 162884-80-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(methylamino)thioxomethyl]hydrazide (CA INDEX NAME)



RN 162884-81-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, 2-[(ethylamino)thioxomethyl]hydrazide (CA INDEX NAME)



RN 162884-83-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 162884-84-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 162884-85-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-methylphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-86-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-87-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-fluorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-88-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-89-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, [(4-bromophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 162884-90-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (4-pyridinylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 162884-91-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, (2-thienylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 162884-92-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-(4-oxo-2-phenyl-3-thiazolidinyl)- (CA INDEX NAME)



RN 162884-93-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-N-[2-(4-methylphenyl)-4-oxo-3-thiazolidinyl]-4-oxo- (CA INDEX NAME)



RN 162884-94-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-[4-oxo-2-(4-pyridinyl)-3-thiazolidinyl]- (CA INDEX NAME)



RN 162884-95-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetamide, 5,6,7,8-tetrahydro-4-oxo-N-[4-oxo-2-(2-thienyl)-3-thiazolidinyl]- (CA INDEX NAME)



L7 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:124483 CAPLUS
DOCUMENT NUMBER: 118:124483
ORIGINAL REFERENCE NO.: 118:21581a,21584a
TITLE: Thieno[2,3-d]pyrimidin-4(3H)-one derivatives and 1,2-dihydrogenated homologs: synthesis, enhanced in vitro antiaggregant activity for reduced compounds
AUTHOR(S): Gravier, D.; Hou, G.; Casadebaig, F.; Dupin, J. P.; Bernard, H.; Boisseau, M.
CORPORATE SOURCE: Lab. Chim. Org., UFR Sci. Pharm., Fr.
SOURCE: Pharmazie (1992), 47(10), 754-7
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I


II

AB Et aminobenzothiophenecarboxylate I cyclized with RCH2NH2 (R = Ph, substituted Ph, cyclohexyl, 2-pyridyl, 2-furyl, etc.) to give benzothienopyrimidinones II (R12 = bond) which were reduced to give II (R1 = H). The platelet antiaggregation activity of II were measured and was found to be comparable and sometimes greater than that of acetylsalicylic acid with serotonin release.

IT 40277-27-8P 146070-98-6P 146070-99-7P
146071-00-3P 146071-01-4P 146071-02-5P
146071-03-6P 146071-04-7P 146071-05-8P
146071-06-9P 146071-07-0P 146071-08-1P
146071-09-2P 146071-10-5P 146071-11-6P
146071-12-7P 146071-13-8P 146071-14-9P
146071-15-0P 146071-16-1P 146071-17-2P
146071-18-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, reduction, and platelet antiaggregation activity of)

RN 40277-27-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 146070-98-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(2-chlorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146070-99-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-00-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)



RN 146071-01-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(3-methylphenyl)methyl]- (CA INDEX NAME)



RN 146071-02-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(4-methylphenyl)methyl]- (CA INDEX NAME)



RN 146071-03-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(2-fluorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-04-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(3-fluorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-05-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(4-fluorophenyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-06-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 146071-07-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 146071-08-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 146071-09-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(cyclohexylmethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-10-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(6,6-dimethylbicyclo[3.1.1]hept-1-yl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-11-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(2-chlorophenyl)ethyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-12-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(3-phenylpropyl)- (CA INDEX NAME)



RN 146071-13-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(1,3-benzodioxol-5-ylmethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-14-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 146071-15-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 146071-16-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-thienylmethyl)- (CA INDEX NAME)



RN 146071-17-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(2-furanylmethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 146071-18-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


S
N
O
N
CH2
O

L7 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:612435 CAPLUS
DOCUMENT NUMBER: 117:212435
ORIGINAL REFERENCE NO.: 117:36699a,36702a
TITLE: Nitriles in heterocyclic synthesis: novel routes to cyclopentenothienopyridines, cyclopentenothienopyrimidenes and cyclopentenopyrrolopyrazoles
AUTHOR(S): Harb, Abdel Fattah Ali
CORPORATE SOURCE: Fac. Sci., Assiut Univ., Kena, Egypt
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1992), 33(1-2), 283-92
CODEN: EJPSBZ; ISSN: 0301-5068
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:212435
GI



I


II


III


IV


V

AB Aminocyclopentenothiophenecarbonitrile I prepared via an extension to the Gewald reaction, was converted into the cyclopentenothienopyridines II (R = H, NH2) and III by treatment with acrylonitrile, malononitrile and Et cyanoacetate. I was converted into the corresponding cyclopentenothienopyrimidines IV (X = S, R1 = NHPh; X = O, R1 = Me, H) on treatment with Ph isothiocyanate, acetic anhydride and triethylorthoformate resp. Also the corresponding cyclopentenopyrrolopyrazole V was obtained by treating I with hydrazine hydrate.
IT 144038-81-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 144038-81-3 CAPLUS
CN 4H-Cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7-tetrahydro-3-

methyl- (CA INDEX NAME)



L7 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:81761 CAPLUS
DOCUMENT NUMBER: 114:81761
ORIGINAL REFERENCE NO.: 114:13957a,13960a
TITLE: Synthesis and antimicrobial activity of some substituted thieno[2,3-d]pyrimidones
AUTHOR(S): El-Enany, M. M.; El-Shafie, F. S.
CORPORATE SOURCE: Coll. Pharm., King Saud Univ., Riyadh, Saudi Arabia
SOURCE: Oriental Journal of Chemistry (1989), 5(2), 114-17
CODEN: OJCHEG; ISSN: 0970-020X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:81761
GI



I

AB Title compds. I [R = NHSO2C6H4R2, R1 = Me, C6H4NO2-4, R2 = H, 4-Me, 2-Br; R = CH2R3, R1 = H, R3 = NMe2, NEt2, N(CH2CH2OH)2, pyrrolidino, 4-methylpiperazino] were prepared I had bactericidal activity against Neisseria and Bacillus subtilis, but showed little activity against Staphylococcus aureus and Escherichia coli.

IT 131928-79-5P 131928-80-8P 131928-81-9P
131928-82-0P 131928-83-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 131928-79-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(dimethylamino)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 131928-80-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[(diethylamino)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 131928-81-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[[bis(2-hydroxyethyl)amino]methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 131928-82-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(1-pyrrolidinylmethyl)- (CA INDEX NAME)



RN 131928-83-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)



L7 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:198412 CAPLUS
DOCUMENT NUMBER: 112:198412
ORIGINAL REFERENCE NO.: 112:33553a,33556a
TITLE: Preparation of 4-oxo-5,6,7,8-tetrahydro-7-benzylpyrido[4',3':4,5]thieno[2,3-d]pyrimidines as antiallergic agents
INVENTOR(S): Kretzschmar, Egon; Laban, Gunter; Meisel, Peter; Kirsten, Wolfgang; Grupe, Renate
PATENT ASSIGNEE(S): VEB Arzneimittelwerk, Ger. Dem. Rep.
SOURCE: Ger. (East), 6 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 272088	A1	19890927	DD 1986-289130	19860415

PRIORITY APPLN. INFO.: DD 1986-289130 19860415
OTHER SOURCE(S): CASREACT 112:198412; MARPAT 112:198412
GI



I



II

AB The title compds. (I; R = H, alkyl) were prepared as antiallergic agents (no data) by cyclocondensation of carbamoylaminotheniopyridines II with orthoformates. Thus, II (R = Pr) was stirred 4 h at 90° with HC(OEt)3 in PhMe containing POCl3 to give I (R = Pr).
IT 126770-01-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergic agent)
RN 126770-01-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-(phenylmethyl)-3-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:23828 CAPLUS
DOCUMENT NUMBER: 110:23828
ORIGINAL REFERENCE NO.: 110:4029a,4032a
TITLE: Synthesis of 2-, 3- and 6-substituted pyrano[4',3':4,5]-thieno-[2,3-d]pyrimidine-4-ones and their anticonvulsive activity
AUTHOR(S): Mkrtchyan, A. P.; Kazaryan, S. G.; Noravyan, A. S.; Vartanyan, S. A.; Dzhagatspanyan, I. A.; Akopyan, N. E.
CORPORATE SOURCE: Inst. Tonk. Org. Khim., Yerevan, USSR
SOURCE: Armyanskii Khimicheskii Zhurnal (1987), 40(9), 581-7
CODEN: AYKZAN; ISSN: 0515-9628
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 110:23828
GI


I


II


III


IV

AB Condensation of pyranones I (X = O, R = H, R1 = Me, Me2CH) with EtO2CCH2CN gave I [X = C(CN)CO2Et] which were cyclized by sulfur to give thienopyrans II. Subsequent acylation gave amides III (R2 = EtO, NH2, R3 = alkyl, chloroalkyl, cyclohexylaminometyl, morpholinoalkyl) which underwent cyclocondensation with R4NH2 (R4 = H, Me, OH) to give pyranothienopyrimidines IV. The latter were potential anticonvulsants (no data).

IT 118005-64-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 118005-64-4 CAPLUS

CN 4H-Pyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,8-tetrahydro-2,3,6,6-tetramethyl- (CA INDEX NAME)



L7 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:21827 CAPLUS
DOCUMENT NUMBER: 108:21827
ORIGINAL REFERENCE NO.: 108:3703a,3706a
TITLE: Thieno compounds. Part 7. Preparation of 2-(arylvinyl)-3,4-dihydro-4-oxothieno[2,3-d]pyrimidines
AUTHOR(S): Thieno-Verbindungen, Ueber
CORPORATE SOURCE: Sekt. Pharm., Martin-Luther-Univ. Halle-Wittenberg, Halle/Saale, Ger. Dem. Rep.
SOURCE: Pharmazie (1987), 42(2), 131
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 108:21827
GI



I



II

AB Title compds. I [R = H, Me, R1 = Me, Ph, RR1 = (CH2)4, R3 = H, Me, R3 = H, p-Cl, p-NO2, m-Cl, o-Cl, m-NO2, o,o'-Cl2, m,p-Cl2] were prepared in 23-85% yield by ZnCl2- catalyzed condensation of methylthienopyrimidinonees II with R3C6H4CHO.

IT 101662-28-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with aromatic aldehydes)

RN 101662-28-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl- (CA INDEX NAME)



L7 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:213890 CAPLUS
DOCUMENT NUMBER: 106:213890
ORIGINAL REFERENCE NO.: 106:34709a,34712a
TITLE: Thieno compounds. 6. Preparation of (3,4-dihydro-4-oxothieno[2,3-d]pyrimidin-3-yl)- and (1,2,3,4-tetrahydro-2,4-dioxothieno[2,3-d]pyrimidinyl)alkanecarboxylic acid derivatives
AUTHOR(S): Boehm, R.; Mueller, R.; Pech, R.
CORPORATE SOURCE: Sekt. Pharm., Martin-Luther-Univ., Halle/Saale, DDR-4020, Ger. Dem. Rep.
SOURCE: Pharmazie (1986), 41(9), 661
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 106:213890
GI


I


II

AB Alkylation of thienopyrimidinones I [R = R1 = Me; R = H, R1 = Ph; RR1 = (CH2)4; R2 = H] with Br(CH2)nCO2Et (n = 1, 2) in presence of NaOH and TEBAC in CH2Cl2-H2O gave I [R2 = (CH2)nCO2Et; n = 1, 2]. Compound II reacted only with bromoacetate and yielded only N-3 substituted derivs.
IT 40277-49-4P 108311-86-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40277-49-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 108311-86-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-propanoic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)


S
N
N
O
O
CH2
CH2
C
OEt

L7 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:176319 CAPLUS
DOCUMENT NUMBER: 106:176319
ORIGINAL REFERENCE NO.: 106:28617a,28620a
TITLE: Heteroannulated pyrimidine-4-ones
AUTHOR(S): Boehm, R.
CORPORATE SOURCE: Sekt. Pharm., Martin-Luther-Univ. Halle-Wittenberg, Halle/Saale, DDR-4020, Ger. Dem. Rep.
SOURCE: Pharmazie (1986), 41(6), 430
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 106:176319
GI



I



II

AB Aminoalkyl derivs. I (R = piperidino) and II (R1 = R, pyrrolidino; n = 1, 2; R2 = H, Me) of the title pyrimidinones were prepared
IT 107640-96-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 107640-96-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(1-piperidinylmethyl)- (CA INDEX NAME)



L7 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:168489 CAPLUS
DOCUMENT NUMBER: 104:168489
ORIGINAL REFERENCE NO.: 104:26699a,26702a
TITLE: 3,4-Dihydro-4-oxo-2-styrylthieno[2,3-d]pyrimidines
INVENTOR(S): Boehm, Ralf; Pech, Reinhard; Laban, Gunter
PATENT ASSIGNEE(S): Martin-Luther-Universitaet Halle-Wittenberg, Ger. Dem. Rep.
SOURCE: Ger. (East), 4 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 225993	A1	19850814	DD 1983-255595	19831012

PRIORITY APPLN. INFO.: DD 1983-255595 19831012
GI



I



II

AB The title compds. [I: R1, R2 = H, alkyl; R1R2 = alkylene; R3 = H, Me; R4 = heteroaryl, (un)substituted aryl], potential pharmaceuticals, were prepared in 23-98% yield by heating the 2-Me derivs. II with R4CHO at .apprx.180° in the presence of ZnCl2 without solvent.
IT 101662-28-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation of, with benzaldehydes)
RN 101662-28-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,3-dimethyl- (CA INDEX NAME)



L7 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:422419 CAPLUS
DOCUMENT NUMBER: 99:22419
ORIGINAL REFERENCE NO.: 99:3629a,3632a
TITLE: Thieno compounds. Part 1. Phase transfer-catalyzed alkylation of thieno[2,3-d]pyrimidin-4(3H)-ones or -2,4-diones
AUTHOR(S): Boehm, R.; Pech, R.; Schneider, E.
CORPORATE SOURCE: Sekt. Pharm., Martin-Luther-Univ. Halle-Wittenberg, Halle/Saale, DDR-4020, Ger. Dem. Rep.
SOURCE: Pharmazie (1983), 38(2), 135-6
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I



II

AB The alkylthienopyrimidinones I and II [R = R1 = Me; R = Ph, R1 = H; RR1 = (CH2)4; R2 = Et, Bu, H2C:CHCH2, Cl(CH2)3, EtO2CCH2, Me] were prepared by alkylation of I and II (R2 = H) with alkyl halides in presence of Et3NCH2Ph Cl-, Bu4N+ Br-, or Bu4N+ HSO4-.
IT 40277-27-8P 40277-49-4P 81136-41-6P
86009-40-7P 86009-41-8P 86009-42-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40277-27-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 40277-49-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 81136-41-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 86009-40-7 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-propyl- (CA INDEX NAME)



RN 86009-41-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-butyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 86009-42-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-(1,1-dimethylethyl)-5,6,7,8-tetrahydro- (CA INDEX NAME)


S
N
N
Bu-t
O

L7 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:122732 CAPLUS
DOCUMENT NUMBER: 96:122732
ORIGINAL REFERENCE NO.: 96:20157a,20160a
TITLE: Thieno[2,3-d]pyrimidines as potential chemotherapeutic agents. II
AUTHOR(S): Ram, Vishnu J.; Pandey, Hrishi Kesh; Vlietinck, Arnold J.
CORPORATE SOURCE: Dep. Chem., S. C. Coll., Ballia, India
SOURCE: Journal of Heterocyclic Chemistry (1981), 18(7), 1277-80
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 96:122732
GI



AB The thiophenecarboxylate I [RR1 = (CH2)4; R = H, R1 = Et] were cyclized with HCONH2 to give the thienopyrimidinones II, which were chlorinated and the thienopyrimidines III (R2 = Cl) aminated to give III (R3 = substituted anilines). III [RR1 = (CH2)4, R2 = Cl] was treated with H2NNH2 followed by PhCHO to give III [RR1 = (CH2)4, R2 = PhCH:NNH], which underwent cyclization to give the triazolopyrimidinobenzothiophene IV. I [RR1 = (CH2)4] was cyclized with R3NCS (R3 = Ph, PhCH2) to give the thienopyrimidines V, which were converted to the S-alkyl derivs. III [RR1 = (CH2)4, R2 = 2-oxo-3-pyrrolidinylmethylenehydrazino] showed some herbicidal activity against velvet leaf (20%).
IT 81136-41-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 81136-41-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)


S
N
N
Et
O

L7 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:35188 CAPLUS
DOCUMENT NUMBER: 96:35188
ORIGINAL REFERENCE NO.: 96:5821a,5824a
TITLE: Synthesis of 2-methyl-3-aryl- or -arylalkyl-5,6-dimethyl- or -polymethylenethieno[2,3-d]pyrimidin-4-ones
AUTHOR(S): Kulshreshtha, M. J.; Bhatt, Shailendra; Pardasani, Madhuri; Khanna, N. M.
CORPORATE SOURCE: Cent. Drug Res. Inst., Lucknow, India
SOURCE: Journal of the Indian Chemical Society (1981), 58(10), 982-4
CODEN: JICSAH; ISSN: 0019-4522
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 96:35188
GI



I


II


III

AB The acetamidothiophenecarboxylic acids I [R = Me, R2 = (CH2)n (n = 3, 4, 5)] were cyclized to give the thienooxazines II, which were treated with primary amines to give the title compds. III (R1 = Ph, o-FC6H4, PhCH2CH2, 3-piperidinopropyl, o-MeC6H4, etc. (55 compds). A few III showed weak diuretic, hypotensive, and antiinflammatory activity.
IT 35973-86-5P 57098-17-6P 80414-23-9P
80414-24-0P 80414-33-1P 80414-34-2P
80414-35-3P 80414-36-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 35973-86-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(2-phenylethyl)- (CA INDEX NAME)



RN 57098-17-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(diethylamino)ethyl]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



RN 80414-23-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-methoxyphenyl)ethyl]-2-methyl- (CA INDEX NAME)



RN 80414-24-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(3,4-dimethoxyphenyl)ethyl]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



RN 80414-33-1 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[2-(diethylamino)ethyl]-3,5,6,7,8,9-hexahydro-2-methyl- (CA INDEX NAME)



RN 80414-34-2 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-2-methyl-3-(2-phenylethyl)- (CA INDEX NAME)



RN 80414-35-3 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3,5,6,7,8,9-hexahydro-3-[2-(4-methoxyphenyl)ethyl]-2-methyl- (CA INDEX NAME)



RN 80414-36-4 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[2-(3,4-dimethoxyphenyl)ethyl]-3,5,6,7,8,9-hexahydro-2-methyl- (CA INDEX NAME)



L7 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:47256 CAPLUS
DOCUMENT NUMBER: 94:47256
ORIGINAL REFERENCE NO.: 94:7713a,7716a
TITLE: Synthesis of some substituted thienopyrimidiones
AUTHOR(S): El-Telbany, Farag A.
CORPORATE SOURCE: Fac. Pharm., Univ. Cairo, Cairo, Egypt
SOURCE: Pharmazie (1980), 35(5-6), 326-7
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 94:47256
GI



I

AB Thienopyrimidinones I [X = NPr, NBu, NCH2CHMe2, cyclohexylamino, 1-naphthylamino, NC6H4I-4, NC6H4OEt-4, NC6H4CO2Et-4, NC6H4OH-4, 4-pyridylamino, 3,4-RCH2(HO)C6H3N, R = NEt2, N(CH2Ph)2, piperidino, 4-methylpiperazino, morpholino] were obtained in 35-85% yield by aminolysis of I (X = O).

IT 76226-43-2P 76226-44-3P 76226-45-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 76226-43-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-propyl- (CA INDEX NAME)



RN 76226-44-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-butyl-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



RN 76226-45-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(2-methylpropyl)- (CA INDEX NAME)



L7 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:186894 CAPLUS
DOCUMENT NUMBER: 90:186894
ORIGINAL REFERENCE NO.: 90:29697a,29700a
TITLE: Thieno[2,3-d]pyrimidines as potential chemotherapeutic agents
AUTHOR(S): Ram, Vishnu Ji
CORPORATE SOURCE: Dep. Chem., S. C. Coll., Ballia, India
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1979), 312(1), 19-25
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 90:186894
GI



I



II

AB Thienopyrimidines I (R = Cl, SH, NHNH2, pyrrolidinoethylamino, morpholinopropylamino, HOCH2CH2NH, (HOCH2CH2)2N, 2-ClC6H4CH2NH, 4-ClC6H4CH2NH, 2,4-Cl2C6H3CH2NH, 2-FC6H4NH, 3-FC6H4NH, 4-FC6H4NH, 4-Et2NC6H4NH, piperidino, OEt, morpholino), II (X = N, CH, CSH, CMeCO), and related compds. were prepared from 4-oxo-5,6,7,8-tetrahydrothianaphtheno[2,3-d]pyrimidine. I (R = Cl) were herbicidal at 8 lb/acre. I (R = SH, NHNH2, NHC6H4F-2, NHC6H4F-3, NHC6H4NEt2-4) were bactericidal against Streptococcus fecales at 64 ppm. I (R = 2,4-Cl2C6H3CH2NH, 2-FC6H4NH) were fungicidal against Pythium at 64 ppm, but that was accompanied by phytotoxicity.
IT 40277-29-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40277-29-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-methyl- (CA INDEX NAME)



L7 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:502375 CAPLUS
DOCUMENT NUMBER: 87:102375
ORIGINAL REFERENCE NO.: 87:16259a,16262a
TITLE: 3-(ω-Alkyl substituted)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine derivatives
INVENTOR(S): Madronero Pelaez, Ramon; Vega Noverola, Salvador; Del Rio Zambrana, Joaquin; Martinez Roldan, Cristobal
PATENT ASSIGNEE(S): Laboratorios Made S. A., Spain
SOURCE: Span., 17 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 425699	A1	19760701	ES 1974-425699	19740426

PRIORITY APPLN. INFO.: ES 1974-425699 A 19740426
GI



I



II



III

AB Thieno[3,2-d]pyrimidinones I [2 = Me2N, Et2N, iso-PrO, morpholino, 1-pyrrolidinyl; n = 2,3; R1 = Me, R2 = H; or R1R2 = (CH2)4 or (CH2)5] were prepared by treatment of the thieno[3,2-d](3,1)oxazinones II with amines R(CH2)nNH2. The ring-opened compds. III were intermediates in some cases. Thus an equimolar mixture of II (R1 = Me, R2 = H) and 2-morpholinoethylamine in benzene was heated 18 h at 130° to give III (R = morpholino, n = 2, R1 = Me, R2 = H), which with polyphosphoric acid at 100° for 3 h and neutralization with 20% aqueous NaOH gave I (same substituents).
IT 57098-15-4P 57098-21-2P 63826-32-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57098-15-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 57098-21-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 63826-32-4 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[3-(dimethylamino)propyl]-3,5,6,7,8,9-hexahydro-2-methyl- (CA INDEX NAME)



L7 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:423197 CAPLUS
DOCUMENT NUMBER: 87:23197
ORIGINAL REFERENCE NO.: 87:3673a,3676a
TITLE: Thiophene bioisosteres. Synthesis of 2-methyl-4-oxothieno [2,3-d] pyrimidines
AUTHOR(S): Noverola, Salvador Vega
CORPORATE SOURCE: Spain
SOURCE: Anales de la Real Academia de Farmacia (1976), 42(4), 563-607
CODEN: ARAFAY; ISSN: 0034-0618
DOCUMENT TYPE: Journal
LANGUAGE: Spanish
OTHER SOURCE(S): CASREACT 87:23197
GI



I


II


III


IV

AB Thienopyrimidinones I [RR1 = (CH2)4, R = Me, R1 = H; R2 = (CH2)3OCHMe2, NHCO2Et, NHCOCH2Ph, NHBz, (CH2)nNR3R4, n = 2, 3, NR3R4 = NMe2, NEt2, morpholino, pyrrolidino] were prepared by treating cyclohexanone and S or HSCH2COMe with NCCH2CO2Et, acetylating II (R5 = H, R6 = Et), hydrolyzing, cyclizing II (R5 = Ac, R6 = H) with Ac2O, and treating the oxazines III with R2NH2 with prolonged heating. Intermediates IV of the reaction of III with R2NH2 were isolated at shorter reaction times.
IT 57098-21-2P 57098-22-3P 57098-23-4P
63003-61-2P 63003-62-3P 63003-63-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57098-21-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 57098-22-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 57098-23-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



RN 63003-61-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(4-morpholinyl)ethyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 57098-15-4
CMF C17 H23 N3 O2 S



CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 63003-62-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(diethylamino)ethyl]-5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 57098-17-6
CMF C17 H25 N3 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 63003-63-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(diethylamino)propyl]-5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 57098-19-8
CMF C18 H27 N3 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L7 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:405893 CAPLUS
DOCUMENT NUMBER: 87:5893
ORIGINAL REFERENCE NO.: 87:949a,952a
TITLE: Heterocyclic compounds. VIII. Synthesis of 3- and 2,3-substituted thienopyrimidones
AUTHOR(S): Manhas, M. S.; Amin, S. G.
CORPORATE SOURCE: Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, USA
SOURCE: Journal of Heterocyclic Chemistry (1977), 14(1), 161-4
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 87:5893
GI



I



II



III



IV

AB Substituted thienopyrimidones ,e.g., I (R = Ph, PhCH2CH2) and II, and quinazolones ,e.g., III, were prepared Thus, the benzothiophene IV (R = H) was formylated to give IV (R = CHO), which was cyclized with PhNH2 to give I (R = Ph).
IT 62821-73-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 62821-73-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-phenylethyl)- (CA INDEX NAME)



L7 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:560152 CAPLUS
Correction of: 1973:29795
DOCUMENT NUMBER: 85:160152
Correction of: 78:29795
ORIGINAL REFERENCE NO.: 85:25645a,25648a
TITLE: Benzothienopyrimidine derivatives
INVENTOR(S): Nakanishi, Michio; Shiraki, Masami
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47042271	B4	19721025	JP 1968-42845	19680620

GI



I

AB The central nervous depressant and antiinflammatory title compds. (I) were prepared E.g., heating 3-methyl-6,7,8,6-tetrahydro-1H-[1]benzothieno[2,3-d]-[1,3]oxazin-1-one and PhNH2 10 min at 60° gave crude crystals which stirred with dicyclohexylcarbodiimide in THF 2 hr at room temperature to gave I (R = H, R1 = Ph, R2 = Me). Similarly, the following I were prepared (R, R1, R2 given): H, p-ClC6H4, Me; H, p-MeOC6H4, Me; H, 2,3-Me2C6H3, Me; H, m-CF3-C6H4, Me; H, p-EtO2C, Me; Me, p-tolyl, Me; Me, PhCH2, Me; Me, Bu, Me; H, Ph, Et; and H, Et, Me.

IT 39625-79-1P 39625-82-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 39625-79-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,7-dimethyl-3-(phenylmethyl)- (CA INDEX NAME)



RN 39625-82-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro-2-

methyl- (CA INDEX NAME)



L7 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:578980 CAPLUS
DOCUMENT NUMBER: 83:178980
ORIGINAL REFERENCE NO.: 83:28109a,28112a
TITLE: Thiophene bioisosteres. II. 2-Methyl-4-oxothieno[3,2-d]pyrimidines and 2-(4H-1,2,4-triazol-4-yl)-3-carboxythiophenes
AUTHOR(S): Lorente, L.; Madronero, R.; Vega, S.
CORPORATE SOURCE: Inst. Quim. Med., Madrid, Spain
SOURCE: Anales de Quimica (1968-1979) (1974), 70(12), 974-9
CODEN: ANQUBU; ISSN: 0365-4990
DOCUMENT TYPE: Journal
LANGUAGE: Spanish
OTHER SOURCE(S): CASREACT 83:178980
GI For diagram(s), see printed CA Issue.
AB Thienopyrimidines I, thiophenes II, and triazolylthiophenes III [RR1 = (CH2)4, R = Me, R1 = H; R2 = aminoalkyl, acylamino, EtO2CNH] were prepared by treating IV with amines; the relative yields of I-III depended on conditions. IV were prepared by cyclizing 2-acetylamino-3-thiophenecarboxylic acids.
IT 57098-16-5P 57098-18-7P 57098-20-1P
57098-21-2P 57098-22-3P 57098-23-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57098-16-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(4-morpholinyl)ethyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 57098-15-4
CMF C17 H23 N3 O2 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 57098-18-7 CAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(diethylamino)ethyl]-
5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 57098-17-6
CMF C17 H25 N3 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 57098-20-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(diethylamino)propyl]-
5,6,7,8-tetrahydro-2-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 57098-19-8
CMF C18 H27 N3 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 57098-21-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 57098-22-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 57098-23-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-methyl- (CA INDEX NAME)



L7 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:124381 CAPLUS
DOCUMENT NUMBER: 78:124381
ORIGINAL REFERENCE NO.: 78:19979a,19982a
TITLE: Synthesis of new heterocycles. VI. Syntheses of certain novel condensed thiophenes
AUTHOR(S): Arya, V. P.
CORPORATE SOURCE: CIBA Res. Cent., Bombay, India
SOURCE: Indian Journal of Chemistry (1972), 10(12), 1141-50
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The synthesis of a number of novel condensed thiophenes from cycloalkanones by the application of the Gewald reaction is described. Cycloalkanones (I) react with nitriles having an active methylene group in the α-position to form substituted nitriles (II). These undergo facile cyclization with S in the presence of diethylamine to give the thiophenes (III). Several reactions of III were explored. For example, some III were cyclized with HC(OEt)3 and Ac2O to lactams. These lactams were converted to tetracyclic heterocycles such as s-triazoles, imidazole, pyrimidine, and tetrazole derivs.
IT 40106-38-5P 40106-39-6P 40106-40-9P
40106-41-0P 40106-42-1P 40106-43-2P
40106-44-3P 40106-57-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40106-38-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(dimethylamino)propyl]-5,6,7,8-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 40106-39-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(4-morpholinyl)ethyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 47198-89-0
CMF C16 H21 N3 O2 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 40106-40-9 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[3-(1-piperidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 40106-41-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-(1-pyrrolidinyl)ethyl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 47130-00-7
CMF C16 H21 N3 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 40106-42-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(dimethylamino)-1-methylethyl]-5,6,7,8-tetrahydro-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 47046-21-9
CMF C15 H21 N3 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 40106-43-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(hexahydro-1H-azepin-1-yl)ethyl]-5,6,7,8-tetrahydro-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 47275-94-5
CMF C18 H25 N3 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 40106-44-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(dimethylamino)propyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 40106-57-8 CAPLUS
CN 4H-Cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one, 3-[3-(dimethylamino)propyl]-3,5,6,7,8,9-hexahydro- (CA INDEX NAME)



L7 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:111243 CAPLUS
DOCUMENT NUMBER: 78:111243
ORIGINAL REFERENCE NO.: 78:17859a,17862a
TITLE: Synthesis of 5,6,7,8-tetrahydrobenzo[1]thieno[2,3,d]py rimidine
AUTHOR(S): Robba, Max; Touzot, Mrs. P.; Riquelme, R. M.
CORPORATE SOURCE: Lab. Pharm. Chim., U.E.R. Sci. Pharm., Caen, Fr.
SOURCE: Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques (1973), 276(1), 93-5
CODEN: CHDCAQ; ISSN: 0567-6541
DOCUMENT TYPE: Journal
LANGUAGE: French
GI For diagram(s), see printed CA Issue.
AB The benzothienopyrimidine I (R = R1 = H) was prepared by dehalogenation of I (R = Cl, R1 = H) via I (R = NHNH2, R1 = H). The benzothienopyrimidinone II (R2 = H) underwent electrophilic substitutions to give II (R2 = Me, CH2Ph, CH2CH:CH2, CH2CO2H, CH2CO2Et, CH2OH, CH2CH2CN). I (R = Cl, R1 = H, Cl) underwent nucleophilic substitutions to give I (R = OMe, OEt, OCH2CH:CH2, OPh, NH2, NHEt, piperidino, morpholino, SPh, SCH2CO2Me; R1 = H) and I (R = R1 = NHNH2; R = NHNH2, H; R1 = Cl). I (R = NHNH2, R1 = H) reacted with HCO2H, AcOH, and HNO2 to give III (X = CH, CMe, N, resp.).
IT 40277-27-8P 40277-29-0P 40277-45-0P
40277-46-1P 40277-47-2P 40277-48-3P
40277-49-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40277-27-8 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 40277-29-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-methyl- (CA INDEX NAME)



RN 40277-45-0 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 40277-46-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 40277-47-2 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-(hydroxymethyl)- (CA INDEX NAME)



RN 40277-48-3 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-propanenitrile, 5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 40277-49-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidine-3(4H)-acetic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)


S
N
N
O
CH2
C
OEt
O

L7 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:29795 CAPLUS
DOCUMENT NUMBER: 78:29795
ORIGINAL REFERENCE NO.: 78:4707a,4710a
TITLE: Benzothienopyrimidine derivatives
INVENTOR(S): Nakanishi, Michio; Shiraki, Masami
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48042271	B4	19721025	JP 1968-42845	19680620

GI For diagram(s), see printed CA Issue.
AB The central nervous depressant and antiinflammatory title compds. (I) were prepared E.g., heating 3-methyl-6,7,8,9-tetrahydro-1H-[1]benzothieno[2,3-d]-[1,3]oxazin-1-one and PhNH2 10 min at 60° gave crude crystals which stirred with dicyclohexylcarbodiimide in THF 2 hr at room temperature to gave I (R = H, R1 = Ph, R2 = Me). Similarly, the following I were prepared (R, R1, R2 given): H, p-ClC6H4, Me; H, p-MeOC6H4, Me; H, 2,3-Me2C6H3, Me; H, m-CF3C6H4, Me; H, p-EtO2C, Me; Me, p-tolyl, Me; Me, PhCH2, Me; Me, Bu, Me; H, Ph, Et; and H, Et, Me.
IT 39625-79-1P 39625-80-4P 39625-82-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39625-79-1 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2,7-dimethyl-3-(phenylmethyl)- (CA INDEX NAME)



RN 39625-80-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-butyl-5,6,7,8-tetrahydro-2,7-dimethyl- (CA INDEX NAME)



RN 39625-82-6 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-ethyl-5,6,7,8-tetrahydro-2-

methyl- (CA INDEX NAME)



L7 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:107846 CAPLUS
DOCUMENT NUMBER: 76:107846
ORIGINAL REFERENCE NO.: 76:17337a,17340a
TITLE: Heterocyclic compounds. 4. Synthesis and antiinflammatory activity of some substituted thienopyrimidones
AUTHOR(S): Manhas, M. S.; Sharma, S. D.; Amin, S. G.
CORPORATE SOURCE: Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, USA
SOURCE: Journal of Medicinal Chemistry (1972), 15(1), 106-7
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Appreciable antiinflammatory activity in the carrageenan-induced edema test in mice was shown by 2-methyl-3-(p-tolyl)-4-oxo-5,6-tetramethylenethieno[2,3-d]pyrimidine (I) [34387-07-0] and the corresponding 3-(p-fluorophenyl) compound (II), which are structural analogs of biol. active substituted quinazolines. The LD50 values of I and II were 1300 and 400 mg/kg i.p., resp., and at 80 mg/kg orally they produced 29.8 and 19.9% inhibition of edema, resp. To synthesize I, 2-amino-4,5-tetramethylenethiophene-3-carboxylic acid was acetylated with Ac2O to form a lactone which was heated with an equivalent amount of p-toluidine.
IT 35973-85-4 35973-86-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory activity of)
RN 35973-85-4 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(phenylmethyl)- (CA INDEX NAME)



RN 35973-86-5 CAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-methyl-3-(2-phenylethyl)- (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 16:54:37 ON 03 JUN 2008)

     FILE 'REGISTRY' ENTERED AT 16:54:48 ON 03 JUN 2008
L1             STRUCTURE UPLOADED
L2           2 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 16:55:18 ON 03 JUN 2008
L3           1 S L2 FULL
L4             STRUCTURE UPLOADED
               S L4

     FILE 'REGISTRY' ENTERED AT 16:56:01 ON 03 JUN 2008
L5         4283 S L4 FULL

     FILE 'CAPLUS' ENTERED AT 16:56:03 ON 03 JUN 2008
L6           44 S L5 FULL

     FILE 'CAPLUS' ENTERED AT 16:56:09 ON 03 JUN 2008
L7           44 S L6 FULL

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 241.24     604.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                 -35.20     -36.00

STN INTERNATIONAL LOGOFF AT 16:57:52 ON 03 JUN 2008
```